Document:

<PAGE>

                                                                   EXHIBIT 10.19

                          SECURITIES PURCHASE AGREEMENT

      SECURITIES PURCHASE AGREEMENT (the "AGREEMENT"), dated as of March 20,
2005, by and among Verilink Corporation, a Delaware corporation, with
headquarters located at 11551 E. Arapahoe Rd., Suite 150, Centennial, Colorado
80112 (the "COMPANY"), and the investors listed on the Schedule of Buyers
attached hereto (individually, a "BUYER" and collectively, the "BUYERS").

      WHEREAS:

      A. The Company and each Buyer is executing and delivering this Agreement
in reliance upon the exemption from securities registration afforded by Section
4(2) of the Securities Act of 1933, as amended (the "1933 ACT"), and Rule 506 of
Regulation D ("REGULATION D") as promulgated by the United States Securities and
Exchange Commission (the "SEC") under the 1933 Act.

      B. The Company has authorized a new series of senior secured convertible
notes of the Company, which notes shall be convertible into the Company's common
stock, $.01 par value per share (the "COMMON STOCK"), in accordance with the
terms of such notes.

      C. Each Buyer wishes to purchase, and the Company wishes to sell, upon the
terms and conditions stated in this Agreement, (i) that aggregate principal
amount of notes, in substantially the form attached hereto as Exhibit A (as
amended or modified from time to time, collectively, the "INITIAL NOTES"), set
forth opposite such Buyer's name in column (3) on the Schedule of Buyers (which
aggregate amount for all Buyers shall be $10,000,000) (as converted,
collectively, the "INITIAL CONVERSION SHARES"), (ii) warrants, in substantially
the form attached hereto as Exhibit B (the "WARRANTS"), to acquire up to that
number of additional shares of Common Stock set forth opposite such Buyer's name
in column (4) of the Schedule of Buyers (as exercised, collectively, the
"WARRANT SHARES") and (iii) a right, in substantially the form attached hereto
as Exhibit C (the "ADDITIONAL INVESTMENT RIGHTS"), to acquire up to that
principal amount of additional notes, in substantially the form attached hereto
as Exhibit D (as amended or modified from time to time, collectively, the
"ADDITIONAL NOTES" and together with the Initial Notes and any senior secured
convertible notes issued in replacement of the Initial Notes or the Additional
Notes in accordance with the terms thereof, the "NOTES"), set forth opposite
such Buyer's name in column (5) on the Schedule of Buyers (such Additional Notes
as converted, the "ADDITIONAL CONVERSION SHARES" and together with the Initial
Conversion Shares, the "CONVERSION SHARES").

      D. The Notes bear interest that, at the option of the Company, subject to
certain conditions, may be paid in shares of Common Stock (the "INTEREST
SHARES").

      E. Contemporaneously with the execution and delivery of this Agreement,
the parties hereto are executing and delivering a Registration Rights Agreement,
substantially in the form attached hereto as Exhibit E (as amended or modified
from time to time in accordance with its terms, the "REGISTRATION RIGHTS
AGREEMENT"), pursuant to which the Company has agreed to provide certain
registration rights with respect to the Conversion Shares, the Warrant Shares
and

<PAGE>

the Interest Shares under the 1933 Act and the rules and regulations promulgated
thereunder, and applicable state securities laws.

      F. The Notes, the Conversion Shares, the Interest Shares, the Warrants,
the Warrant Shares and the Additional Investment Rights collectively are
referred to herein as the "SECURITIES".

      G. Except as otherwise set forth herein, the Notes will be (i) senior to
all outstanding and future indebtedness of the Company, (ii) secured by a
perfected security interest in all of the assets of the Company and in all of
the assets of the "EXISTING SUBSIDIARIES" as evidenced by (and as defined in)
the Pledge and Security Agreement in favor of Portside Growth & Opportunity
Fund, a company organized under the laws of the Cayman Islands, in its capacity
as collateral agent (in such capacity, the "SENIOR AGENT") for the Buyers hereto
and for the other holders of the Securities, in the form attached hereto as
Exhibit F (as amended or modified from time to time, the "PLEDGE AND SECURITY
AGREEMENT"), which security interest shall be senior to all other security
interests therein, and (iii) guaranteed by the Guarantee of each of the Existing
Subsidiaries, in the form attached hereto as Exhibit G (such Guaranty, together
with the Pledge and Security Agreement, as each may amended or modified from
time to time, collectively, the "SECURITY DOCUMENTS").

      NOW, THEREFORE, the Company and each Buyer hereby agree as follows:

      1. PURCHASE AND SALE OF NOTES, WARRANTS AND ADDITIONAL INVESTMENT RIGHTS.

            (a) Purchase of Notes, Warrants and Additional Investment Rights.

                  (i) Subject to the satisfaction (or waiver) of the conditions
set forth in Sections 7 and 8(a) below, the Company shall issue and sell to each
Buyer, and each Buyer severally, but not jointly, agrees to purchase from the
Company on the Closing Date (as defined below), (A) one or more Notes with an
aggregate principal amount as is set forth opposite such Buyer's name in column
(3) on the Schedule of Buyers, (B) one or more Warrants to acquire up to that
number of Warrant Shares as is set forth opposite such Buyer's name in column
(4) on the Schedule of Buyers and (C) Additional Investment Rights to acquire up
to that principal amount of Additional Notes as is set forth opposite such
Buyer's name in column (5) on the Schedule of Buyers (the "CLOSING").

                  (ii) Closing. The date and time of the Closing (the "CLOSING
DATE") shall be 10:00 a.m., New York City time, on the date hereof (or such
later date as is mutually agreed to by the Company and each Buyer) after
notification of satisfaction (or waiver) of the conditions to the Closing set
forth in Sections 7 and 8(a) below at the offices of Schulte Roth & Zabel LLP,
919 Third Avenue, New York, New York 10022. Upon purchase of Additional
Investment Rights at the Closing, each Buyer shall be deemed to have agreed
expressly to its obligations with respect to Mandatory Funding (as defined in
the Additional Investment Right issued to it).

                  (iii) Purchase Price. The aggregate purchase price for the
Notes, the Warrants and the Additional Investment Rights to be purchased by each
Buyer at the Closing

                                      -2-
<PAGE>

(the "PURCHASE PRICE") shall be the amount set forth opposite such Buyer's name
in column (6) of the Schedule of Buyers. Each Buyer shall pay $1.00 for each
$1.00 of principal amount of Initial Notes and related Warrants and Additional
Investment Rights to be purchased by such Buyer at the Closing.

            (b) Form of Payment. On the Closing Date, (i) each Buyer shall pay
its Purchase Price to the Company for the Initial Notes, the Warrants and the
Additional Investment Rights to be issued and sold to such Buyer at the Closing,
by wire transfer of immediately available funds in accordance with the Company's
written wire instructions, and (ii) the Company shall deliver to each Buyer (A)
the Initial Notes (allocated in the principal amounts as such Buyer shall
request) which such Buyer is then purchasing, (B) the Warrants (allocated in the
amounts as such Buyer shall request) such Buyer is purchasing and (C) the
Additional Investment Rights (allocated in the amounts as such Buyer shall
request) such Buyer is purchasing, in each case duly executed on behalf of the
Company and registered in the name of such Buyer or its designee.

      2. BUYER'S REPRESENTATIONS AND WARRANTIES.

            Each Buyer represents and warrants with respect to only itself that:

            (a) No Sale or Distribution. Such Buyer is acquiring the Notes, the
Warrants and the Additional Investment Rights, and upon conversion of the Notes
and exercise of the Warrants and Additional Investment Rights will acquire the
Conversion Shares issuable upon conversion of the Notes, the Warrant Shares
issuable upon exercise of the Warrants and the Additional Notes issuable upon
exercise of the Additional Investment Rights, for its own account and not with a
view towards, or for resale in connection with, the sale or distribution
thereof, except pursuant to sales registered or exempted under the 1933 Act;
provided, however, that by making the representations herein, such Buyer does
not agree to hold any of the Securities for any minimum or other specific term
and reserves the right to dispose of the Securities at any time in accordance
with or pursuant to a registration statement or an exemption under the 1933 Act.
Such Buyer is acquiring the Securities hereunder in the ordinary course of its
business. Such Buyer does not presently have any agreement or understanding,
directly or indirectly, with any Person (as defined in Section 3(s)) to
distribute any of the Securities.

            (b) Accredited Investor / Qualified Institutional Buyer Status. Such
Buyer is an "accredited investor" as that term is defined in Rule 501(a) of
Regulation D that is an institution and to the extent indicated in the Schedule
of Buyers, a "qualified institutional buyer" as that term is defined in Rule
144A of the Securities Act.

            (c) Non-Affiliate Status. Such Buyer is not an affiliate of the
Company or of any other Buyer and is not acting in concert with any other Person
in regard to the purchase of Notes, Warrants and Additional Investment Rights or
otherwise in respect of the Company. Such Buyer's investment in Notes, Warrants
and Additional Investment Rights is not for the purpose of acquiring, directly
or indirectly, control of, and it has not intent to acquire or exercise control
or, the Company or to influence the decisions or policies of the Board of
Directors of the Company.

                                      -3-
<PAGE>

            (d) Reliance on Exemptions. Such Buyer understands that the
Securities are being offered and sold to it in reliance on specific exemptions
from the registration requirements of United States federal and state securities
laws and that the Company is relying in part upon the truth and accuracy of, and
such Buyer's compliance with, the representations, warranties, agreements,
acknowledgments and understandings of such Buyer set forth herein in order to
determine the availability of such exemptions and the eligibility of such Buyer
to acquire the Securities.

            (e) Information. Such Buyer and its advisors, if any, have been
furnished with or provided with access to all materials relating to the
business, finances and operations of the Company and materials relating to the
offer and sale of the Securities that have been requested by such Buyer. Such
Buyer and its advisors, if any, have been afforded the opportunity to ask
questions of the Company. Neither such inquiries nor any other due diligence
investigations conducted by such Buyer or its advisors, if any, or its
representatives shall modify, amend or affect such Buyer's right to rely on the
Company's representations and warranties contained herein. Such Buyer
understands that its investment in the Securities involves a high degree of risk
and is able to afford a complete loss of such investment. Such Buyer has sought
such accounting, legal and tax advice as it has considered necessary to make an
informed investment decision with respect to its acquisition of the Securities.

            (f) No Governmental Review. Such Buyer understands that no United
States federal or state agency or any other government or governmental agency
has passed on or made any recommendation or endorsement of the Securities or the
fairness or suitability of the investment in the Securities nor have such
authorities passed upon or endorsed the merits of the offering of the
Securities.

            (g) Transfer or Resale. Such Buyer understands that: (i) the
Securities have not been and, except as provided in the Registration Rights
Agreement are not being registered under the 1933 Act or any state securities
laws, and may not be offered for sale, sold, assigned or transferred unless (A)
subsequently registered thereunder, (B) such Buyer shall have delivered to the
Company an opinion of counsel, reasonably acceptable to the Company, to the
effect that such Securities to be sold, assigned or transferred may be sold,
assigned or transferred pursuant to an exemption from such registration, or (C)
such Securities are sold, assigned or transferred pursuant to Rule 144 or Rule
144A promulgated under the 1933 Act, as amended (or a successor rule thereto)
(collectively, "RULE 144"); (ii) any sale of the Securities made in reliance on
Rule 144 may be made only in accordance with the terms of Rule 144 and further,
if Rule 144 is not applicable, any resale of the Securities under circumstances
in which the seller (or the Person through whom the sale is made) may be deemed
to be an underwriter (as that term is defined in the 1933 Act) may require
compliance with some other exemption under the 1933 Act or the rules and
regulations of the SEC thereunder; and (iii) except as provided in the
Registration Rights Agreement, neither the Company nor any other Person is under
any obligation to register the Securities under the 1933 Act or any state
securities laws or to comply with the terms and conditions of any exemption
thereunder.

            (h) Legends. Such Buyer understands that the certificates or other
instruments representing the Notes, Warrants and Additional Investment Rights
and the stock certificates representing the Conversion Shares and the Warrant
Shares, except as set forth below, shall bear

                                      -4-
<PAGE>

any legend as required by the "blue sky" laws of any state and a restrictive
legend in substantially the following form (and a stop-transfer order may be
placed against transfer of such stock certificates):

            [NEITHER THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS
            CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE
            [CONVERTIBLE] [EXERCISABLE] HAVE BEEN][THE SECURITIES REPRESENTED BY
            THIS CERTIFICATE HAVE NOT BEEN] REGISTERED UNDER THE SECURITIES ACT
            OF 1933, AS AMENDED (THE :SECURITIES ACT"), OR APPLICABLE STATE
            SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD,
            TRANSFERRED OR ASSIGNED IN THE ABSENCE OF (A) AN EFFECTIVE
            REGISTRATION STATEMENT FOR THE SECURITIES UNDER THE SECURITIES ACT,
            (B) AN OPINION OF COUNSEL, REASONABLY ACCEPTABLE TO THE COMPANY,
            THAT REGISTRATION IS NOT REQUIRED UNDER SAID ACT OR (C) REASONABLE
            ASSURANCE HAVING BEEN PROVIDED TO THE COMPANY THAT SUCH OFFER, SALE,
            ASSIGNMENT OR TRANSFER IS BEING MADE PURSUANT TO RULE 144 OR RULE
            144A UNDER SAID ACT. NOTWITHSTANDING THE FOREGOING, THE SECURITIES
            MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT OR
            OTHER LOAN OR FINANCING ARRANGEMENT SECURED BY THE SECURITIES.

The legend set forth above shall be removed and the Company shall issue a
certificate without such legend to the transferee of the Securities, if, unless
otherwise required by state securities laws, (i) the sale of such Securities has
been registered for resale under the 1933 Act; provided, that the holder of
Securities shall be required to provide appropriate evidence that such sale was
effected under the related registration statement, (ii) in connection with a
sale, assignment or other transfer, such holder provides the Company with an
opinion of counsel, reasonably acceptable to the Company, to the effect that
such sale, assignment or transfer of the Securities is being made pursuant to an
exemption from the registration requirements the 1933 Act, or (iii) such holder
provides the Company with reasonable assurance that the Securities are being
sold, assigned or transferred pursuant to Rule 144 or Rule 144A.

            (i) Validity; Enforcement. This Agreement, the Registration Rights
Agreement and the Security Documents to which such Buyer is a party have been
duly and validly authorized, executed and delivered on behalf of such Buyer and
shall constitute the legal, valid and binding obligations of such Buyer
enforceable against such Buyer in accordance with their respective terms, except
as such enforceability may be limited by general principles of equity or to
applicable bankruptcy, insolvency, reorganization, moratorium, liquidation and
other similar laws relating to, or affecting generally, the enforcement of
applicable creditors' rights and remedies.

            (j) No Conflicts. The execution, delivery and performance by such
Buyer of this Agreement, the Registration Rights Agreement and the Security
Documents to which such Buyer

                                      -5-
<PAGE>

is a party and the consummation by such Buyer of the transactions contemplated
hereby and thereby will not (i) result in a violation of the organizational
documents of such Buyer or (ii) conflict with, or constitute a default (or an
event which with notice or lapse of time or both would become a default) under,
or give to others any rights of termination, amendment, acceleration or
cancellation of, any agreement, indenture or instrument to which such Buyer is a
party, or (iii) result in a violation of any law, rule, regulation, order,
judgment or decree (including federal and state securities laws) applicable to
such Buyer, except in the case of clauses (ii) and (iii) above, for such
conflicts, defaults, rights or violations which would not, individually or in
the aggregate, reasonably be expected to have a material adverse effect on the
ability of such Buyer to perform its obligations hereunder.

            (k) Residency. Such Buyer is a resident of that jurisdiction
specified below its address on the Schedule of Buyers.

      3. REPRESENTATIONS AND WARRANTIES OF THE COMPANY.

            The Company represents and warrants to each of the Buyers that:

            (a) Organization and Qualification. Except as set forth on Schedule
3(a), the Company and its "SUBSIDIARIES" (which for purposes of this Agreement
means any entity in which the Company, directly or indirectly, owns 50% or more
of the outstanding capital stock or holds an equity or similar interest
representing 50% or more of the outstanding equity or similar interest of such
entity) are entities duly organized and validly existing and, to the extent
legally applicable, in good standing under the laws of the jurisdiction in which
they are formed, and have the requisite power and authority to own their
properties and to carry on their business as now being conducted. Except as set
forth on Schedule 3(a), each of the Company and its Subsidiaries is duly
qualified as a foreign entity to do business and, to the extent legally
applicable, is in good standing in every jurisdiction in which its ownership of
property or the nature of the business conducted by it makes such qualification
necessary, except to the extent that the failure to be so qualified or be in
good standing would not have a Material Adverse Effect. As used in this
Agreement, "MATERIAL ADVERSE EFFECT" means any material adverse effect on the
business, properties, assets, operations, results of operations or condition
(financial or otherwise) of the Company and its Subsidiaries, taken as a whole,
or on the transactions contemplated hereby and in the Security Documents or by
the agreements and instruments to be entered into in connection herewith or
therewith, or on the authority or ability of the Company to perform its
obligations under the Transaction Documents (as defined below). The Company does
not hold any equity or similar interest in any entity except as set forth on
Schedule 3(a).

            (b) Authorization; Enforcement; Validity. The Company has the
requisite power and authority to enter into and perform its obligations under
this Agreement, the Notes, the Registration Rights Agreement, the Security
Documents, the Irrevocable Transfer Agent Instructions (as defined in Section
5(b)), the Warrants, the Additional Investment Rights and the Voting Agreement
(as defined in Section 4(q)) (collectively, the "TRANSACTION DOCUMENTS") and to
issue the Securities in accordance with the terms hereof and thereof. The
execution and delivery of the Transaction Documents by the Company and the
consummation by the Company of the transactions contemplated hereby and thereby,
including, without limitation, the issuance of the Notes, the Warrants and the
Additional Investment Rights, the reservation for issuance and

                                      -6-
<PAGE>

the issuance of the Conversion Shares issuable upon conversion of the Notes, the
reservation for issuance and issuance of Warrant Shares issuable upon exercise
of the Warrants, and the granting of a security interest in the Collateral (as
defined in the Security Documents) have been duly authorized by the Company's
Board of Directors and, other than the filings specified in Section 3(e) or as
otherwise contemplated herein or in the Transaction Documents, no further
consent or authorization is required by the Company, its Board of Directors or
its stockholders. This Agreement and the other Transaction Documents of even
date herewith have been duly executed and delivered by the Company, and
constitute the legal, valid and binding obligations of the Company, enforceable
against the Company in accordance with their respective terms, except (i) as
such enforceability may be limited by general principles of equity or applicable
bankruptcy, insolvency, reorganization, moratorium, liquidation or similar laws
relating to, or affecting generally, the enforcement of applicable creditors'
rights and remedies, and (ii) to the extent that the enforceability of the
indemnification provisions herein or therein may be limited by applicable laws.
As of the date of issuance of any Additional Notes, such Additional Notes shall
have been duly executed and delivered by the Company, and shall constitute the
legal, valid and binding obligations of the Company, enforceable against the
Company in accordance with their respective terms, except (i) as such
enforceability may be limited by general principles of equity or applicable
bankruptcy, insolvency, reorganization, moratorium, liquidation or similar laws
relating to, or affecting generally, the enforcement of applicable creditor's
rights and remedies, and (ii) to the extent that the enforceability of the
indemnification provisions herein or therein may be limited by applicable laws.

            (c) Issuance of Securities. The issuance of the Notes, the Warrants
and the Additional Investment Rights are duly authorized and, upon issuance in
accordance with the terms hereof and the Transaction Documents, will be free
from all taxes, liens and charges with respect to the issue thereof. As of the
Closing, at least 9,182,979 shares of Common Stock shall have been duly
authorized and reserved for issuance as Interest Shares and as shares issuable
upon conversion of the Notes or exercise of the Warrants. Upon issuance or
conversion in accordance with the Notes or exercise in accordance with the
Warrants, as the case may be, the Interest Shares, the Conversion Shares and the
Warrant Shares, respectively, will be validly issued, fully paid and
nonassessable and free from all preemptive or similar rights, taxes, liens and
charges with respect to the issue thereof, with the holders being entitled to
all rights accorded to a holder of Common Stock; provided, however, that such
Conversion Shares and Warrants Shares may be subject to restrictions on transfer
under state and/or federal securities laws. Assuming the accuracy of each of the
representations and warranties set forth in Section 2 of this Agreement, the
offer and issuance by the Company of the Securities is exempt from registration
under the 1933 Act.

            (d) No Conflicts. Except as set forth on Schedule 3(d), the
execution, delivery and performance of the Transaction Documents by the Company
and the consummation by the Company of the transactions contemplated hereby and
thereby (including, without limitation, the issuance of the Notes, the Warrants
and the Additional Investment Rights, the granting of a security interest in the
Collateral (as defined in the Security Documents) and reservation for issuance
and issuance of the Interest Shares, the Conversion Shares and the Warrant
Shares) will not (i) result in a violation of any certificate of incorporation,
certificate of formation, any certificate of designations or other constituent
documents of the Company or any of its Subsidiaries or bylaws of the Company or
any of its Subsidiaries or (ii) conflict with, or

                                      -7-
<PAGE>

constitute a default (or an event which with notice or lapse of time or both
would become a default) in any material respect under, or give to others any
rights of termination, amendment, acceleration or cancellation of, any material
agreement, indenture or instrument to which the Company or any of its
Subsidiaries is a party, or (iii) result in a violation of any law, rule,
regulation, order, judgment or decree (including federal and state securities
laws and regulations and the rules and regulations of the Nasdaq National Market
(the "PRINCIPAL MARKET")) applicable to the Company or any of its Subsidiaries
or by which any property or asset of the Company or any of its Subsidiaries is
bound or affected, except, in the case of clause (iii), for such violations as
would not be reasonably expected to have a Material Adverse Effect.

            (e) Consents. The Company is not required to obtain any consent,
authorization or order of, or make any filing or registration with, any court,
governmental agency or any regulatory or self-regulatory agency or any other
Person in order for it to execute, deliver or perform any of its obligations
under or contemplated by the Transaction Documents, in each case in accordance
with the terms hereof or thereof, except as contemplated herein and except for
the following consents, authorizations, orders, filings and registrations (none
of which, other than in clause (iii), is required to be filed or obtained before
the Closing): (i) the filing of appropriate UCC financing statements with the
appropriate states and authorities pursuant to the Pledge and Security
Agreement, (ii) the filing with the SEC of one or more Registration Statements
in accordance with the requirements of the Registration Rights Agreement and
(iii) the filing of a listing application for the Conversion Shares, Interest
Shares and Warrant Shares with the Principal Market, which shall be done
pursuant to the rules of the Principal Market. The Company and its Subsidiaries
are unaware of any facts or circumstances that might prevent the Company from
obtaining or effecting any of the registration, application or filings pursuant
to the preceding sentence. The Company is not in violation of the listing
requirements of the Principal Market and has no knowledge of any facts that
would reasonably lead to delisting or suspension of the Common Stock in the
foreseeable future.

            (f) Acknowledgment Regarding Buyer's Purchase of Securities. The
Company acknowledges and agrees that each Buyer is acting solely in the capacity
of arm's length purchaser with respect to the Transaction Documents and the
transactions contemplated hereby and thereby. The Company further acknowledges
that no Buyer is acting as a financial advisor or fiduciary of the Company (or
in any similar capacity) with respect to the Transaction Documents and the
transactions contemplated hereby and thereby, and any advice given by a Buyer or
any of its representatives or agents in connection with the Transaction
Documents and the transactions contemplated hereby and thereby is merely
incidental to such Buyer's purchase of the Securities. The Company further
represents to each Buyer that the Company's decision to enter into the
Transaction Documents has been based solely on the independent evaluation by the
Company and its representatives.

            (g) No General Solicitation; Placement Agent's Fees. Neither the
Company, nor any of its affiliates, nor any Person acting on its or their
behalf, has engaged in any form of general solicitation or general advertising
(within the meaning of Regulation D) in connection with the offer or sale of the
Securities. The Company acknowledges that it has engaged Kaufman Bros., L.P. as
placement agent (the "AGENT") in connection with the sale of the Securities.
Other than the Agent, the Company has not engaged any placement agent or other
agent in connection with the sale of the Securities.

                                      -8-
<PAGE>

            (h) No Integrated Offering. None of the Company, its Subsidiaries,
any of their affiliates, and any Person acting on their behalf has, directly or
indirectly, made any offers or sales of any security or solicited any offers to
buy any security, under circumstances that would require registration of any of
the Securities under the 1933 Act or cause this offering of the Securities to be
integrated with prior offerings by the Company for purposes of the 1933 Act or
any applicable stockholder approval provisions, including, without limitation,
under the rules and regulations of any exchange or automated quotation system on
which any of the securities of the Company are listed or designated.

            (i) Dilutive Effect. The Company understands and acknowledges that
the number of Conversion Shares issuable upon conversion of the Notes and the
Warrant Shares issuable upon exercise of the Warrants will increase in certain
circumstances. The Company further acknowledges that its obligation to issue
Conversion Shares upon conversion of the Notes in accordance with this Agreement
and the Notes and its obligation to issue the Warrant Shares upon exercise of
the Warrants in accordance with this Agreement and the Warrants is, in each
case, absolute and unconditional regardless of the dilutive effect that such
issuance may have on the ownership interests of other stockholders of the
Company.

            (j) Application of Takeover Protections; Rights Agreement. The
Company and its board of directors have taken all necessary action, if any, in
order to render inapplicable any control share acquisition, business
combination, poison pill (including any distribution under a rights agreement)
or other similar anti-takeover provision under the Certificate of Incorporation
or the laws of the jurisdiction of its formation which is or could become
applicable to any Buyer as a result of the transactions contemplated by this
Agreement, including, without limitation, the Company's issuance of the
Securities and any Buyer's ownership of the Securities. Except as set forth on
Schedule 3(j), the Company has not adopted a stockholder rights plan or similar
arrangement relating to accumulations of beneficial ownership of Common Stock or
a change in control of the Company.

            (k) SEC Documents; Financial Statements. Except as set forth on
Schedule 3(k), during the twelve (12) month prior to the date hereof, the
Company has filed all reports, schedules, forms, statements and other documents
required to be filed by it with the SEC pursuant to the reporting requirements
of the Securities Exchange Act of 1934, as amended (the "1934 ACT") (all of the
foregoing filed prior to the date hereof and all exhibits included therein and
financial statements, notes and schedules thereto and documents (other than
exhibits) incorporated by reference therein being hereinafter referred to as the
"SEC DOCUMENTS"). The Company has made available to the Buyers or their
respective representatives true, correct and complete copies of the SEC
Documents not available on the EDGAR system (other than any correspondence filed
by the Company with the SEC, including without limitation, any confidential
treatment requests). As of their respective dates, the SEC Documents complied in
all material respects with the requirements of the 1934 Act and the rules and
regulations of the SEC promulgated thereunder applicable to the SEC Documents,
and none of the SEC Documents, at the time they were filed with the SEC,
contained any untrue statement of a material fact or omitted to state a material
fact required to be stated therein or necessary in order to make the statements
therein, in the light of the circumstances under which they were made, not
misleading. As of their respective dates, the financial statements of the
Company included in the SEC Documents complied as to form in all material
respects with applicable accounting

                                      -9-
<PAGE>

requirements and the published rules and regulations of the SEC with respect
thereto. Such financial statements have been prepared in accordance with
generally accepted accounting principles, consistently applied, during the
periods involved (except (i) as may be otherwise indicated in such financial
statements or the notes thereto, or (ii) in the case of unaudited interim
statements, to the extent they may exclude footnotes or may be condensed or
summary statements) and fairly present in all material respects the financial
position of the Company as of the dates thereof and the results of its
operations and cash flows for the periods then ended (subject, in the case of
unaudited statements, to normal year-end audit adjustments).

            (l) Absence of Certain Changes. Except as disclosed in Schedule
3(l), since July 2, 2004, there has been no material adverse change and no
material adverse development in the business, properties, operations, condition
(financial or otherwise) or results of operations of the Company or its
Subsidiaries. Except as disclosed in Schedule 3(l), since July 2, 2004, the
Company has not (i) declared or paid any dividends, (ii) sold any assets,
individually or in the aggregate, in excess of $100,000 outside of the ordinary
course of business or (iii) had capital expenditures, individually or in the
aggregate, in excess of $500,000. The Company has not taken any steps to seek
protection pursuant to any bankruptcy law nor does the Company have any
knowledge or reason to believe that its creditors intend to initiate involuntary
bankruptcy proceedings or any actual knowledge of any fact that would reasonably
lead a creditor to do so. Except as disclosed in Schedule 3(l), the Company and
its Subsidiaries, individually and on a consolidated basis, are not as of the
date hereof, and after giving effect to the transactions contemplated hereby to
occur at the Closing, will not be Insolvent (as defined below). For purposes of
this Section 3(l), "Insolvent" means, with respect to any Person (as defined in
Section 3(s)), (i) the present fair saleable value of such Person's assets is
less than the amount required to pay such Person's total Indebtedness (as
defined in Section 3(s)), (ii) the Company is unable to pay its debts and
liabilities, subordinated, contingent or otherwise, as such debts and
liabilities become absolute and matured, (iii) such Person intends to incur or
believes that it will incur debts that would be beyond its ability to pay as
such debts mature or (iv) such Person has unreasonably small capital with which
to conduct the business in which it is engaged as such business is now conducted
and is proposed to be conducted.

            (m) No Undisclosed Events, Liabilities, Developments or
Circumstances. Other than as to the transactions set forth in the Transaction
Documents, no event, liability, development or circumstance has occurred or
exists, or is contemplated to occur with respect to the Company or its
Subsidiaries or their respective business, properties, operations or financial
condition, that would be required to be disclosed by the Company under
applicable securities laws on a registration statement on Form S-1 filed with
the SEC relating to an issuance and sale by the Company of its Common Stock and
which has not been publicly announced.

            (n) Conduct of Business; Regulatory Permits. Neither the Company nor
its Subsidiaries is in violation of any term of or in default under its
Certificate of Incorporation or Bylaws or their organizational charter or
certificate of incorporation or bylaws, respectively. Neither the Company nor
any of its Subsidiaries is in violation of any judgment, decree or order or any
statute, ordinance, rule or regulation applicable to the Company or its
Subsidiaries in respect of the conduct of its business or the ownership of its
properties, except for possible violations which would not, individually or in
the aggregate, have a Material Adverse Effect. Without limiting the generality
of the foregoing, the Company is not in violation of any of the

                                      -10-
<PAGE>

rules, regulations or requirements of the Principal Market and has no knowledge
of any facts or circumstances that would reasonably lead to delisting or
suspension of the Common Stock by the Principal Market in the foreseeable
future. Since December 31, 2003, (i) the Common Stock has been designated for
quotation on the Principal Market, (ii) trading in the Common Stock has not been
suspended by the SEC or the Principal Market and (iii) the Company has received
no communication, written or oral, from the SEC or the Principal Market
regarding the suspension or delisting of the Common Stock from the Principal
Market. The Company and its Subsidiaries possess all certificates,
authorizations and permits issued by the appropriate regulatory authorities
necessary to conduct their respective businesses, except where the failure to
possess such certificates, authorizations or permits would not have,
individually or in the aggregate, a Material Adverse Effect, and neither the
Company nor any such Subsidiary has received any notice of proceedings relating
to the revocation or modification of any such certificate, authorization or
permit.

            (o) Foreign Corrupt Practices. Neither the Company, nor any of its
Subsidiaries, nor any director, officer, agent, employee or other Person acting
on behalf of the Company or any of its Subsidiaries has, in the course of its
actions for, or on behalf of, the Company (i) used any corporate funds for any
unlawful contribution, gift, entertainment or other unlawful expenses relating
to political activity; (ii) made any direct or indirect unlawful payment to any
foreign or domestic government official or employee from corporate funds; (iii)
violated or is in violation of any provision of the U.S. Foreign Corrupt
Practices Act of 1977, as amended; or (iv) made any unlawful bribe, rebate,
payoff, influence payment, kickback or other unlawful payment to any foreign or
domestic government official or employee.

            (p) Sarbanes-Oxley Act. The Company is in compliance with any and
all applicable requirements of the Sarbanes-Oxley Act of 2002 that are effective
as of the date hereof, and any and all applicable rules and regulations
promulgated by the SEC thereunder that are effective as of the date hereof,
except where such noncompliance would not have, individually or in the
aggregate, a Material Adverse Effect.

            (q) Transactions With Affiliates. Except as set forth in the SEC
Documents filed at least two days prior to the date hereof and other than the
grant of stock incentives issued pursuant to employee benefit plans disclosed in
the SEC Documents, none of the officers, directors or employees of the Company
is presently a party to any transaction with the Company or any of its
Subsidiaries (other than for ordinary course services as employees, officers or
directors), including any contract, agreement or other arrangement providing for
the furnishing of services to or by, providing for rental of real or personal
property to or from, or otherwise requiring payments to or from any such
officer, director or employee or, to the knowledge of the Company, any
corporation, partnership, trust or other entity in which any such officer,
director, or employee has a substantial interest or is an officer, director,
trustee or partner.

            (r) Equity Capitalization. The capitalization of the Company is as
described in the SEC Documents. All of such outstanding shares have been validly
issued and are fully paid and nonassessable. Except as disclosed in Schedule
3(r): (i) none of the Company's share capital is subject to preemptive rights or
any other similar rights or any liens or encumbrances suffered or permitted by
the Company; (ii) other than pursuant to employee benefit plans disclosed in the
SEC Documents, there are no outstanding options, warrants, scrip, rights to
subscribe to, calls or

                                      -11-
<PAGE>

commitments of any character whatsoever relating to, or securities or rights
convertible into, or exercisable or exchangeable for, any share capital of the
Company or any of its Subsidiaries, or contracts, commitments, understandings or
arrangements by which the Company or any of its Subsidiaries is or may become
bound to issue additional share capital of the Company or any of its
Subsidiaries or options, warrants, scrip, rights to subscribe to, calls or
commitments of any character whatsoever relating to, or securities or rights
convertible into, or exercisable or exchangeable for, any share capital of the
Company or any of its Subsidiaries; (iii) there are no outstanding debt
securities, notes, credit agreements, credit facilities or other agreements,
documents or instruments evidencing Indebtedness (as defined in Section 3(s)) of
the Company or any of its Subsidiaries or by which the Company or any of its
Subsidiaries is or may become bound; (iv) there are no financing statements
securing obligations in any material amounts, either singly or in the aggregate,
filed in connection with the Company; (v) there are no agreements or
arrangements under which the Company or any of its Subsidiaries is obligated to
register the sale of any of their securities under the 1933 Act (except the
Registration Rights Agreement); (vi) there are no outstanding securities or
instruments of the Company or any of its Subsidiaries which contain any
redemption or similar provisions, and there are no contracts, commitments,
understandings or arrangements by which the Company or any of its Subsidiaries
is or may become bound to redeem a security of the Company or any of its
Subsidiaries; (vii) there are no securities or instruments containing
anti-dilution or similar provisions that will be triggered by the issuance of
the Securities; (viii) the Company does not have any stock appreciation rights
or "phantom stock" plans or agreements or any similar plan or agreement; and
(ix) the Company and its Subsidiaries have no liabilities or obligations
required to be disclosed in the SEC Documents but not so disclosed in the SEC
Documents, other than those incurred in the ordinary course of the Company's or
its Subsidiaries' respective businesses since September 30, 2004 and which,
individually or in the aggregate, do not or would not have a Material Adverse
Effect. The Company has made available to the Buyer true, correct and complete
copies of the Company's Certificate of Incorporation, as amended and as in
effect on the date hereof (the "CERTIFICATE OF INCORPORATION"), and the
Company's Bylaws, as amended and as in effect on the date hereof (the "BYLAWS"),
and the terms of all securities convertible into, or exercisable or exchangeable
for, shares of Common Stock and the material rights of the holders thereof in
respect thereto.

            (s) Indebtedness and Other Contracts. Except as disclosed in
Schedule 3(s), neither the Company nor any of its Subsidiaries (i) has any
outstanding Indebtedness (as defined below), (ii) is a party to any contract,
agreement or instrument, the reasonably foreseeable violation of which, or
reasonably foreseeable default under which, by the other party(ies) to such
contract, agreement or instrument could reasonably be expected to result in a
Material Adverse Effect, (iii) is in violation of any term of or in default
under any contract, agreement or instrument relating to any Indebtedness, except
where such violations and defaults would not result, individually or in the
aggregate, in a Material Adverse Effect, or (iv) is a party to any contract,
agreement or instrument relating to any Indebtedness, the performance of which,
in the judgment of the Company's officers, has or is expected to have a Material
Adverse Effect. For purposes of this Agreement: (x) "INDEBTEDNESS" of any Person
means, without duplication (A) all indebtedness for borrowed money, (B) all
obligations issued, undertaken or assumed as the deferred purchase price of
property or services, including (without limitation) "capital leases" in
accordance with generally accepted accounting principals (other than trade
payables entered into in the ordinary course of business), (C) all reimbursement
or payment obligations with respect to letters of credit, surety bonds and other
similar instruments, (D) all obligations evidenced by

                                      -12-
<PAGE>

notes, bonds, debentures or similar instruments, including obligations so
evidenced incurred in connection with the acquisition of property, assets or
businesses, (E) all indebtedness created or arising under any conditional sale
or other title retention agreement, or incurred as financing, in either case
with respect to any property or assets acquired with the proceeds of such
indebtedness (even though the rights and remedies of the seller or bank under
such agreement in the event of default are limited to repossession or sale of
such property), (F) all monetary obligations under any leasing or similar
arrangement which, in connection with generally accepted accounting principles,
consistently applied for the periods covered thereby, is classified as a capital
lease, (G) all indebtedness referred to in clauses (A) through (F) above secured
by (or for which the holder of such Indebtedness has an existing right,
contingent or otherwise, to be secured by) any mortgage, lien, pledge, charge,
security interest or other encumbrance upon or in any property or assets
(including accounts and contract rights) owned by any Person, even though the
Person which owns such assets or property has not assumed or become liable for
the payment of such indebtedness, and (H) all Contingent Obligations in respect
of indebtedness or obligations of others of the kinds referred to in clauses (A)
through (G) above; (y) "CONTINGENT OBLIGATION" means, as to any Person, any
direct or indirect liability, contingent or otherwise, of that Person with
respect to any indebtedness, lease, dividend or other obligation of another
Person if the primary purpose or intent of the Person incurring such liability,
or the primary effect thereof, is to provide assurance to the obligee of such
liability that such liability will be paid or discharged, or that any agreements
relating thereto will be complied with, or that the holders of such liability
will be protected (in whole or in part) against loss with respect thereto; and
(z) "PERSON" means an individual, a limited liability company, a partnership, a
joint venture, a corporation, a trust, an unincorporated organization and a
government or any department or agency thereof.

            (t) Absence of Litigation. Except as set forth in Schedule 3(t),
there is no action, suit, proceeding, inquiry or investigation before or by the
Principal Market, any court, public board, government agency, self-regulatory
organization or body pending or, to the knowledge of the Company, threatened
against or affecting the Company, the Common Stock or any of the Company's
Subsidiaries or any of the Company's or the Company's Subsidiaries' officers or
directors in their capacities as such that if determined adversely to the
Company could, individually or in the aggregate, reasonably be expected to have
a Material Adverse Effect.

            (u) Insurance. The Company and each of its Subsidiaries are insured
by insurers of recognized financial responsibility against such losses and risks
and in such amounts as management of the Company believes to be prudent and
customary in the businesses in which the Company and its Subsidiaries are
engaged. Neither the Company nor any such Subsidiary has, in the previous twelve
(12) months, been refused any insurance coverage sought or applied for and
neither the Company nor any such Subsidiary has any reason to believe that it
will not be able to renew its existing insurance coverage as and when such
coverage expires or to obtain similar coverage from similar insurers as may be
necessary to continue its business at a cost that would not have a Material
Adverse Effect.

            (v) Employee Relations. (i) Except as disclosed in the SEC Documents
or in Schedule 3(v), neither the Company nor any of its Subsidiaries is a party
to any collective bargaining agreement or employs any member of a union. Except
as disclosed in Schedule 3(v), no executive officer of the Company (as defined
in Rule 501(f) of the 1933 Act) has notified the Company that such officer
intends to leave the Company or otherwise terminate such officer's

                                      -13-
<PAGE>

employment with the Company or, to the knowledge of the Company, is, or is now
expected to be, in violation of any material term of any employment contract,
confidentiality, disclosure or proprietary information agreement,
non-competition agreement, or any other contract or agreement or any restrictive
covenant, and the continued employment of each such executive officer does not
subject the Company or any of its Subsidiaries to any material liability with
respect to any of the foregoing matters.

                  (ii) The Company and its Subsidiaries are in compliance with
all federal, state, local and foreign laws and regulations respecting labor,
employment and employment practices and benefits, terms and conditions of
employment and wages and hours, except where failure to be in compliance would
not, either individually or in the aggregate, reasonably be expected to result
in a Material Adverse Effect.

            (w) Title. Except as set forth on Schedule 3(w), the Company and its
Subsidiaries have good and marketable title in fee simple to all real property
and good and marketable title to all personal property owned by them which is
material to the business of the Company and its Subsidiaries, in each case free
and clear of all liens, encumbrances and defects except such as do not
materially affect the value of such property and do not interfere with the use
made and proposed to be made of such property by the Company and any of its
Subsidiaries. Any real property and facilities held under lease by the Company
and any of its Subsidiaries are held by them under valid, subsisting and
enforceable leases with such exceptions as are not material and do not interfere
with the use made and proposed to be made of such property and buildings by the
Company and its Subsidiaries.

            (x) Intellectual Property Rights. The Company and its Subsidiaries
own or possess adequate rights or licenses to use all trademarks, service marks
and all applications and registrations therefor, trade names, patents, patent
rights, copyrights, original works of authorship, inventions, trade secrets and
other intellectual property rights ("INTELLECTUAL PROPERTY RIGHTS") necessary to
conduct their respective businesses as now conducted. Except as set forth in
Schedule 3(x), none of the Company's registered, or applied for, Intellectual
Property Rights have expired or terminated or have been abandoned, or are
expected to expire or terminate or expected to be abandoned, within three years
from the date of this Agreement except where the expiration or termination would
not reasonably be expected to have a Material Adverse Effect. The Company does
not have any knowledge of any infringement by the Company or its Subsidiaries of
Intellectual Property Rights of others. There is no claim, action or proceeding
being made or brought, or to the knowledge of the Company, being threatened in
writing, against the Company or its Subsidiaries regarding its Intellectual
Property Rights. The Company is unaware of any facts or circumstances which
might give rise to any of the foregoing infringements or claims, actions or
proceedings. The Company and its Subsidiaries have taken reasonable security
measures to protect the secrecy, confidentiality and value of all of their
Intellectual Property Rights.

            (y) Environmental Laws. The Company and its Subsidiaries (i) are in
compliance with any and all Environmental Laws (as hereinafter defined), (ii)
have received all permits, licenses or other approvals required of them under
applicable Environmental Laws to conduct their respective businesses and (iii)
are in compliance with all terms and conditions of any such permit, license or
approval where, in each of the foregoing clauses (i), (ii) and (iii), the
failure to

                                      -14-
<PAGE>

so comply could be reasonably expected to have, individually or in the
aggregate, a Material Adverse Effect. The term "ENVIRONMENTAL LAWS" means all
federal, state, local or foreign laws relating to pollution or protection of
human health or the environment (including, without limitation, ambient air,
surface water, groundwater, land surface or subsurface strata), including,
without limitation, laws relating to emissions, discharges, releases or
threatened releases of chemicals, pollutants, contaminants, or toxic or
hazardous substances or wastes (collectively, "HAZARDOUS MATERIALS") into the
environment, or otherwise relating to the manufacture, processing, distribution,
use, treatment, storage, disposal, transport or handling of Hazardous Materials,
as well as all authorizations, codes, decrees, demands or demand letters,
injunctions, judgments, licenses, notices or notice letters, orders, permits,
plans or regulations issued, entered, promulgated or approved thereunder.

            (z) Alabama Mortgage. As of the date hereof, the outstanding loan
amounts secured by the Alabama Mortgage (as defined in the Notes) is in the
aggregate, not in excess of $3,500,000.

            (aa) No Outstanding Default. After using portion of the proceeds
from the sale of the Securities to repay all amounts outstanding or otherwise
owing to RBC Centura Bank, neither the Company nor any of its Subsidiaries shall
be in default under any material agreement, indenture or instrument to which the
Company or any of its Subsidiaries is a party.

            (bb) Subsidiary Rights. The Company or one of its Subsidiaries has
the unrestricted right to vote, and (subject to limitations imposed by
applicable law) to receive dividends and distributions on, all capital
securities of its Subsidiaries as owned by the Company or such Subsidiary.

            (cc) Tax Status. Except as set forth in Schedule 3(cc), the Company
and each of its Subsidiaries (i) has made or filed all foreign, federal and
state income and all other tax returns, reports and declarations required by any
jurisdiction to which it is subject, (ii) has paid all taxes and other
governmental assessments and charges that are material in amount, shown or
determined to be due on such returns, reports and declarations, except those
being contested in good faith and (iii) has set aside on its books provision
reasonably adequate for the payment of all taxes for periods subsequent to the
periods to which such returns, reports or declarations apply where, in each of
the foregoing clauses (i), (ii) and (iii), the failure to do so could be
reasonably expected to have, individually or in the aggregate, a Material
Adverse Effect. There are no unpaid taxes in any material amount claimed to be
due by the taxing authority of any jurisdiction, and the Company knows of no
basis for any such claim.

            (dd) Internal Accounting and Disclosure Controls. The Company and
each of its Subsidiaries maintain a system of internal accounting controls
sufficient to provide reasonable assurance that (i) transactions are executed in
accordance with management's general or specific authorizations, (ii)
transactions are recorded as necessary to permit preparation of financial
statements in conformity with generally accepted accounting principles and to
maintain asset and liability accountability, (iii) access to assets or
incurrence of liabilities is permitted only in accordance with management's
general or specific authorization and (iv) the recorded accountability for
assets and liabilities is compared with the existing assets and liabilities at
reasonable intervals and appropriate action is taken with respect to any
difference. The

                                      -15-
<PAGE>

Company maintains disclosure controls and procedures (as such term is defined in
Rule 13a-14 under the 1934 Act) that are effective in ensuring that information
required to be disclosed by the Company in the reports that it files or submits
under the 1934 Act is recorded, processed, summarized and reported, within the
time periods specified in the rules and forms of the SEC, including, without
limitation, controls and procedures designed in to ensure that information
required to be disclosed by the Company in the reports that it files or submits
under the 1934 Act is accumulated and communicated to the Company's management,
including its principal executive officer or officers and its principal
financial officer or officers, as appropriate, to allow timely decisions
regarding required disclosure.

            (ee) Off Balance Sheet Arrangements. There is no transaction,
arrangement, or other relationship between the Company and an unconsolidated or
other off balance sheet entity that is required to be disclosed by the Company
in its Exchange Act filings and is not so disclosed or that otherwise would be
reasonably likely to have a Material Adverse Effect.

            (ff) Ranking of Notes. Except as disclosed in Schedule 3(ff), no
Indebtedness of the Company is senior to or ranks pari passu with the Notes in
right of payment, whether with respect of payment of redemptions, interest,
damages or upon liquidation or dissolution or otherwise.

            (gg) Form S-3 Eligibility. The Company is currently eligible to
register the Conversion Shares, the Warrant Shares and the Interest Shares for
resale by the Buyers using Form S-3 promulgated under the 1933 Act.

            (hh) Manipulation of Price. The Company has not, and to its
knowledge no one acting on its behalf has, (i) taken, directly or indirectly,
any action designed to cause or to result in the stabilization or manipulation
of the price of any security of the Company to facilitate the sale or resale of
any of the Securities, (ii) sold, bid for, purchased, or paid any compensation
for soliciting purchases of, any of the Securities, or (iii) paid or agreed to
pay to any person any compensation for soliciting another to purchase any other
securities of the Company.

            (ii) Disclosure. Other than as to the transactions set forth in the
Transaction Documents which will be publicly disclosed as part of the Form 8-K
Filing (as defined below), the Company confirms that neither it nor any other
Person acting on its behalf has provided any of the Buyers or their agents or
counsel with any information that constitutes material, nonpublic information.
The Company understands and confirms that each of the Buyers will rely on the
foregoing representations in effecting transactions in securities of the
Company. All disclosure provided to the Buyers regarding the Company, its
business and the transactions contemplated hereby, including the Disclosure
Schedule delivered to the Buyers in connection with this Agreement, is true and
correct and does not contain any untrue statement of a material fact or omit to
state any material fact necessary in order to make the statements made therein,
in the light of the circumstances under which they were made, not misleading.
Except as set forth in Schedule 3(ii), each press release issued by the Company
during the twelve (12) months preceding the date of this Agreement did not at
the time of release contain any untrue statement of a material fact or omit to
state a material fact required to be stated therein or necessary in order to
make the statements therein, in the light of the circumstances under which they
were made, not misleading. No event or circumstance has occurred or information
exists with respect to the Company or any of its

                                      -16-
<PAGE>

Subsidiaries or its or their business, properties, operations or financial
conditions, which, under applicable law, rule or regulation, requires public
disclosure or announcement by the Company but which has not been so publicly
announced or disclosed.

            (jj) Acknowledgement Regarding Buyers' Trading Activity. Anything in
this Agreement or elsewhere herein to the contrary notwithstanding, but subject
to compliance by the Buyers with applicable law, it is understood and
acknowledged by the Company (i) that none of the Buyers have been asked to
agree, nor has any Buyer agreed, to desist from purchasing or selling, long
and/or short, securities of the Company, or "derivative" securities based on
securities issued by the Company or to hold the Securities for any specified
term; (ii) that past or future open market or other transactions by any Buyer,
including, without limitation, short sales or "derivative" transactions, before
or after the closing of this or future private placement transactions, may
negatively impact the market price of the Company's publicly-traded securities;
(iii) that any Buyer, and counter parties in "derivative" transactions to which
any such Buyer is a party, directly or indirectly, presently may have a "short"
position in the Common Stock, and (iv) that each Buyer shall not be deemed to
have any affiliation with or control over any arm's length counter-party in any
"derivative" transaction. The Company further understands and acknowledges that
(a) one or more Buyers may engage in hedging activities at various times during
the period that the Securities are outstanding, including, without limitation,
during the periods that the value of the Conversion Shares and Interest Shares
deliverable with respect to Securities are being determined and (b) such hedging
activities (if any) could reduce the value of the existing stockholders' equity
interests in the Company at and after the time that the hedging activities are
being conducted.

      4. COVENANTS.

            (a) Best Efforts. Each party shall use its best efforts timely to
satisfy each of the conditions to be satisfied by it as provided in Sections 7
and 8 of this Agreement.

            (b) Form D and Blue Sky. The Company agrees to file a Form D with
respect to the Securities as required under Regulation D and to provide a copy
thereof to each Buyer promptly after such filing. The Company shall, on or
before the Closing Date, take such action as the Company shall reasonably
determine is necessary in order to obtain an exemption for or to qualify the
Securities for sale to the Buyers at the Closing pursuant to this Agreement
under applicable securities or "Blue Sky" laws of the states of the United
States (or to obtain an exemption from such qualification), and shall provide
evidence of any such action so taken to the Buyers on or prior to the Closing
Date. The Company shall make all filings and reports relating to the offer and
sale of the Securities required under applicable securities or "Blue Sky" laws
of the states of the United States following the Closing Date; provided,
however, that the Company shall not for any such purpose be required to qualify
generally to transact business as a foreign corporation in any jurisdiction
where it is not so qualified or to consent to general service of process in any
such jurisdiction.

            (c) Reporting Status. Until the date on which the Investors (as
defined in the Registration Rights Agreement) no longer hold any Conversion
Shares, Warrant Shares and Interest Shares and none of the Notes, Warrants or
Additional Investment Rights is outstanding (the "REPORTING PERIOD"), and other
than in accordance with the Notes, Warrants and the

                                      -17-
<PAGE>

Additional Investment Rights, the Company shall timely file all reports required
to be filed with the SEC pursuant to the 1934 Act, and the Company shall
continue to timely file reports under the 1934 Act even if the 1934 Act or the
rules and regulations thereunder would otherwise no longer require such filings;
provided, that each Investor shall upon request of the Company notify the
Company if such Investor holds any Securities, and the Company shall be entitled
to conclude that no Securities are so held unless notice that Securities are so
held has been provided to the Company within 30 days of such request.

            (d) Use of Proceeds. The Company will use the proceeds from the sale
of the Securities to repay all amounts outstanding or otherwise owing to RBC
Centura Bank and for working capital purposes. The Company will not use the
proceeds from the sale of the Securities for the (i) repayment of any other
outstanding Indebtedness of the Company or any of its Subsidiaries or (ii)
redemption or repurchase of any of its equity securities.

            (e) Financial Information. The Company agrees to send the following
to each Investor during the Reporting Period, unless the following are filed
with the SEC through EDGAR and are available to the public through the EDGAR
system (i) within one (1) Business Day after the filing thereof with the SEC, a
copy of its Annual Reports on Form 10-K its Quarterly Reports on Form 10-Q, any
Current Reports on Form 8-K and any registration statements (other than on Form
S-8) or amendments filed pursuant to the 1933 Act, (ii) on the same day as the
release thereof, facsimile copies of all press releases issued by the Company or
any of its Subsidiaries, and (iii) copies of any notices and other information
made available or given to the stockholders of the Company generally,
contemporaneously with the making available or giving thereof to the
stockholders; provided, however, that the Company shall have no obligation
hereunder to provide copies of any correspondence filed with the SEC, including,
without limitation, any confidential treatment requests. For purposes of this
Agreement, "BUSINESS DAY" means any day other than Saturday, Sunday or other day
on which commercial banks in The City of New York are authorized or required by
law to remain closed.

            (f) Listing. The Company shall promptly secure the listing of all of
the Registrable Securities (as defined in the Registration Rights Agreement)
upon each national securities exchange and automated quotation system, if any,
upon which the Common Stock is then listed (subject to official notice of
issuance) and shall maintain, so long as any other shares of Common Stock shall
be so listed and in accordance with the Notes, Warrants and Additional
Investment Rights, such listing of all Registrable Securities from time to time
issuable under the terms of the Transaction Documents. The Company shall
maintain the Common Stocks' authorization for quotation on the Principal Market;
provided, however, that the Company makes no covenant regarding applicable
listing standards based the trading price of the Common Stock. Neither the
Company nor any of its Subsidiaries shall take any action which would be
reasonably expected to result in the delisting or suspension of the Common Stock
on the Principal Market. The Company shall pay all fees and expenses in
connection with satisfying its obligations under this Section 4(f).

            (g) Fees. Subject to Section 9 below, the Company shall promptly pay
an expense allowance to Portside Growth & Opportunity Fund (a Buyer) or its
designee(s) (in addition to any other expense amounts paid to any Buyer prior to
the date of this Agreement) to cover expenses reasonably incurred by Portside
Growth & Opportunity Fund or any

                                      -18-
<PAGE>

professionals engaged by Portside Growth & Opportunity Fund in relation (i) to
due diligence and investment documentation, in an amount not to exceed $120,000
(in addition to any other expense amounts paid to any Buyer prior to the date of
this Agreement), which amount shall be withheld by such Buyer from its Purchase
Price at the Closing and (ii) to the post-Closing items in connection with
Section 8(b) hereof, in an amount not to exceed $25,000. The Company shall also
reimburse Portside Growth & Opportunity Fund for the costs of performing UCC,
tax and judgment lien searches and searches with the United States Patent and
Trademark Office, in an amount not to exceed $3,000, which costs shall not be
deducted from the expense reimbursement set forth in the immediately preceding
sentence. The Company shall be responsible for the payment of any placement
agent's fees, financial advisory fees, or broker's commissions (other than for
Persons engaged by any Buyer) relating to or arising out of the transactions
contemplated hereby, including, without limitation, any fees or commissions
payable to the Agent (collectively, the "COMMISSIONS"). The Company shall pay,
and hold each Buyer harmless against, any liability, loss or expense (including,
without limitation, reasonable attorney's fees and out-of-pocket expenses)
arising in connection with any claim relating to any Commissions. Except as
otherwise set forth in the Transaction Documents, each party to this Agreement
shall bear its own expenses in connection with the sale of the Securities to the
Buyers.

            (h) Pledge of Securities. The Company acknowledges and agrees that,
subject to applicable state and federal securities laws, the Securities may be
pledged by an Investor (as defined in the Registration Rights Agreement) in
connection with a bona fide margin agreement or other loan or financing
arrangement that is secured by the Securities. The pledge of Securities shall
not be deemed to be a transfer, sale or assignment of the Securities hereunder,
and no Investor effecting a pledge of Securities shall be required to provide
the Company with any notice thereof or otherwise make any delivery to the
Company pursuant to this Agreement or any other Transaction Document, including,
without limitation, Section 2(g) hereof; provided that an Investor and its
pledgee shall be required to comply with the provisions of Section 2(g) hereof
in order to effect a sale, transfer or assignment of Securities to such pledgee.
The Company hereby agrees to execute and deliver such documentation as a pledgee
of the Securities may reasonably request in connection with a pledge of the
Securities to such pledgee by an Investor.

            (i) Disclosure of Transactions and Other Material Information. On or
before 8:30 a.m., New York time, ON the first Business Day following the date of
this Agreement, the Company shall file a Current Report on Form 8-K describing
the terms of the transactions contemplated by the Transaction Documents in the
form required by the 1934 Act and attaching the material Transaction Documents
(including, without limitation, this Agreement, the form of each of the Notes,
the form of Warrant, the form of Additional Investment Right, the Registration
Rights Agreement, the Voting Agreement and the Security Documents) as exhibits
to such filing (including all attachments, the "8-K FILING"). From and after the
filing of the 8-K Filing with the SEC, no Buyer shall be in possession of any
material, nonpublic information received from the Company, any of its
Subsidiaries or any of its respective officers, directors, employees or agents,
that is not disclosed in the 8-K Filing. The Company shall not, and shall cause
each of its Subsidiaries and its and each of their respective officers,
directors, employees and agents, not to, provide any Buyer with any material,
nonpublic information regarding the Company or any of its Subsidiaries from and
after the filing of the 8-K Filing with the SEC without the express written
consent of such Buyer. If a Buyer has, or believes it has, received

                                      -19-
<PAGE>

any such material, nonpublic information regarding the Company or any of its
Subsidiaries, it shall provide the Company with written notice thereof. The
Company shall, within five (5) Trading Days of receipt of such notice, make
public disclosure of any such material, nonpublic information. In the event of a
breach of the foregoing covenant by the Company, any of its Subsidiaries, or any
of its or their respective officers, directors, employees and agents, in
addition to any other remedy provided herein or in the Transaction Documents, a
Buyer shall have the right to make a public disclosure, in the form of a press
release, public advertisement or otherwise, of such material, nonpublic
information without the prior approval by the Company, its Subsidiaries, or any
of its or their respective officers, directors, employees or agents. No Buyer
shall have any liability to the Company, its Subsidiaries, or any of its or
their respective officers, directors, employees, stockholders or agents for any
such disclosure. Subject to the foregoing, neither the Company nor any Buyer
shall issue any press releases or any other public statements with respect to
the transactions contemplated hereby; provided, however, that the Company shall
be entitled, without the prior approval of any Buyer, to make any press release
or other public disclosure with respect to such transactions (i) in substantial
conformity with the 8-K Filing and contemporaneously therewith or (ii) as is
required by applicable law and regulations (provided that in the case of clause
(i) each Buyer shall be consulted by the Company in connection with any such
press release or other public disclosure prior to its release).

            (j) Restriction on Redemption and Cash Dividends. So long as any
Notes or Additional Investment Rights are outstanding, the Company shall not,
directly or indirectly, redeem, or declare or pay any cash dividend or
distribution on, the Common Stock without the prior express written consent of
the holders of Notes representing not less than a majority of the aggregate
principal amount of the then outstanding Notes (the "REQUIRED HOLDERS").

            (k) Additional Registration Statements. Until the date that the
Registration Statement (as defined in the Registration Rights Agreement) is
first declared effective by the SEC (the "EFFECTIVE DATE"), the Company shall
not file a registration statement under the 1933 Act relating to securities that
are not the Securities.

            (l) No Integrated Offering. None of the Company, its Subsidiaries,
their affiliates and any Person acting on their behalf will take any action or
steps referred to in Section 3(h) that would require registration of any of the
Securities under the 1933 Act or cause the offering of the Securities to be
integrated with other offerings.

            (m) Additional Notes; Variable Securities; Dilutive Issuances. So
long as any Buyer beneficially owns any Securities, the Company will not issue
any Notes other than to the Buyers as contemplated hereby and the Company shall
not issue any other securities that would cause a breach or default under the
Notes. For so long as any Notes, Additional Investment Rights or Warrants remain
outstanding, the Company shall not, without the written consent of the Required
Holders, in any manner, issue or sell any rights, warrants or options to
subscribe for or purchase Common Stock or directly or indirectly convertible
into or exchangeable or exercisable for Common Stock at a price which varies or
may vary with the market price of the Common Stock, including by way of one or
more reset(s) to any fixed price unless the conversion, exchange or exercise
price of any such security cannot be less than the then applicable Conversion
Price (as defined in the Notes) with respect to the Common Stock into which any
Note is convertible or the then applicable Exercise Price (as defined in the
Warrants)

                                      -20-
<PAGE>

with respect to the Common Stock into which any Warrant is exercisable. For so
long as any Notes, Warrants or Additional Investment Rights remain outstanding,
the Company shall not, without the written consent of the Required Holders, in
any manner, enter into or affect any Dilutive Issuance (as defined in the Notes)
if the effect of such Dilutive Issuance is to cause the Company to be required
to issue upon conversion of any Note or exercise of any Warrant any shares of
Common Stock in excess of that number of shares of Common Stock which the
Company may issue upon conversion of the Notes, including the Additional Notes,
and exercise of the Warrants without breaching the Company's obligations under
the rules or regulations of the Principal Market.

            (n) Corporate Existence. So long as any Buyer beneficially owns any
Securities, the Company shall not be party to any Fundamental Transaction (as
defined in the Notes) unless the Company is in compliance with the applicable
provisions governing Fundamental Transactions set forth in the Notes, the
Warrants and the Additional Investment Rights.

            (o) Reservation of Shares. The Company shall take all action
necessary to at all times have authorized, and reserved for the purpose of
issuance, after the Closing Date, 150% of the number of Interest Shares issuable
pursuant to the terms of the Notes (assuming that all principal payments on such
Notes are made in a timely fashion and that the Notes are not redeemed or
converted before maturity, that all interest payments on such Notes are made in
Interest Shares and that the number of Interest Shares is determined based on
the Interest Conversion Price (as defined in the Notes), as of the trading date
immediately preceding the applicable date of determination), shares of Common
Stock issuable upon conversion of all of the Notes (including the Additional
Notes) and shares of Common Stock issuable upon exercise of the Warrants.

            (p) Conduct of Business. The business of the Company and its
Subsidiaries shall not be conducted in violation of any law, ordinance or
regulation of any governmental entity, except where such violations would not
result, either individually or in the aggregate, in a Material Adverse Effect.

            (q) Additional Issuances of Securities.

                  (i) For purposes of this Section 4(q), the following
definitions shall apply.

                        (1) "CONVERTIBLE SECURITIES" means any stock or
      securities (other than Options) convertible into or exercisable or
      exchangeable for shares of Common Stock.

                        (2) "OPTIONS" means any rights, warrants or options to
      subscribe for or purchase shares of Common Stock or Convertible
      Securities.

                        (3) "COMMON STOCK EQUIVALENTS" means, collectively,
      Options and Convertible Securities.

                  (ii) From the date hereof until the date that is 90 Trading
Days (as defined in the Notes) following the Effective Date (as defined in the
Registration Rights

                                      -21-
<PAGE>

Agreement) (the "TRIGGER DATE"), the Company will not, directly or indirectly,
offer, sell, grant any option to purchase, or otherwise dispose of (or announce
any offer, sale, grant or any option to purchase or other disposition of) any of
its or its Subsidiaries' equity or equity equivalent securities, including
without limitation any debt, preferred stock or other instrument or security
that is, at any time during its life and under any circumstances, convertible
into or exchangeable or exercisable for shares of Common Stock or Common Stock
Equivalents, except for Excluded Securities (as defined in the Notes) (any such
offer, sale, grant, disposition or announcement being referred to as a
"SUBSEQUENT PLACEMENT").

                  (iii) From the Trigger Date until the two year anniversary of
the Closing Date, the Company will not, directly or indirectly, effect any
Subsequent Placement unless the Company shall have first complied with this
Section 4(q)(iii).

                        (1) The Company shall deliver to each Buyer a written
      notice (the "OFFER NOTICE") of any proposed or intended issuance or sale
      or exchange (the "OFFER") of the securities being offered (the "OFFERED
      SECURITIES") in a Subsequent Placement, which Offer Notice shall (w)
      identify and describe the Offered Securities, (x) describe the price and
      other terms upon which they are to be issued, sold or exchanged, and the
      number or amount of the Offered Securities to be issued, sold or
      exchanged, (y) identify the persons or entities (if known) to which or
      with which the Offered Securities are to be offered, issued, sold or
      exchanged and (z) offer to issue and sell to or exchange with such Buyers
      a pro rata portion of 30% of the Offered Securities allocated among such
      Buyers (a) based on such Buyer's pro rata portion of the aggregate
      principal amount of Notes purchased hereunder (the "BASIC AMOUNT"), and
      (b) with respect to each Buyer that elects to purchase its Basic Amount,
      any additional portion of the Offered Securities attributable to the Basic
      Amounts of other Buyers as such Buyer shall indicate it will purchase or
      acquire should the other Buyers subscribe for less than their Basic
      Amounts (the "UNDERSUBSCRIPTION AMOUNT").

                        (2) To accept an Offer, in whole or in part, such Buyer
      must deliver a written notice to the Company prior to the end of the tenth
      (10th) Business Day after such Buyer's receipt of the Offer Notice (the
      "OFFER PERIOD"), setting forth the portion of such Buyer's Basic Amount
      that such Buyer elects to purchase and, if such Buyer shall elect to
      purchase all of its Basic Amount, the Undersubscription Amount, if any,
      that such Buyer elects to purchase (in either case, the "NOTICE OF
      ACCEPTANCE"). If the Basic Amounts subscribed for by all Buyers are less
      than the total of all of the Basic Amounts, then each Buyer who has set
      forth an Undersubscription Amount in its Notice of Acceptance shall be
      entitled to purchase, in addition to the Basic Amounts subscribed for, the
      Undersubscription Amount it has subscribed for; provided, however, that if
      the Undersubscription Amounts subscribed for exceed the difference between
      the total of all the Basic Amounts and the Basic Amounts subscribed for
      (the "AVAILABLE UNDERSUBSCRIPTION AMOUNT"), each Buyer who has subscribed
      for any Undersubscription Amount shall be entitled to purchase only that
      portion of the Available Undersubscription Amount as the Basic Amount of
      such Buyer bears to the total Basic Amounts of all Buyers that have
      subscribed for Undersubscription Amounts, subject to rounding by the
      Company to the extent its deems reasonably necessary.

                                      -22-
<PAGE>

                        (3) The Company shall have ten (10) Business Days from
      the expiration of the Offer Period above to offer, issue, sell or exchange
      all or any part of such Offered Securities as to which a Notice of
      Acceptance has not been given by the Buyers (the "REFUSED SECURITIES"),
      but only to the offerees described in the Offer Notice (if so described
      therein) and only upon terms and conditions (including, without
      limitation, unit prices and interest rates) that are not more favorable to
      the acquiring person or persons or less favorable to the Company than
      those set forth in the Offer Notice.

                        (4) In the event the Company shall propose to sell less
      than all the Refused Securities (any such sale to be in the manner and on
      the terms specified in Section 4(q)(iii)(3) above), then each Buyer may,
      at its sole option and in its sole discretion, reduce the number or amount
      of the Offered Securities specified in its Notice of Acceptance to an
      amount that shall be not less than the number or amount of the Offered
      Securities that such Buyer elected to purchase pursuant to Section
      4(q)(iii)(2) above multiplied by a fraction, (i) the numerator of which
      shall be the number or amount of Offered Securities the Company actually
      proposes to issue, sell or exchange (including Offered Securities to be
      issued or sold to Buyers pursuant to Section 4(q)(iii)(3) above prior to
      such reduction) and (ii) the denominator of which shall be the original
      amount of the Offered Securities. In the event that any Buyer so elects to
      reduce the number or amount of Offered Securities specified in its Notice
      of Acceptance, the Company may not issue, sell or exchange more than the
      reduced number or amount of the Offered Securities unless and until such
      securities have again been offered to the Buyers in accordance with
      Section 4(q)(iii)(1) above.

                        (5) Upon the closing of the issuance, sale or exchange
      of all or less than all of the Refused Securities, the Buyers shall
      acquire from the Company, and the Company shall issue to the Buyers, the
      number or amount of Offered Securities specified in the Notices of
      Acceptance, as reduced pursuant to Section 4(q)(iii)(4) above if the
      Buyers have so elected, upon the terms and conditions specified in the
      Offer. The purchase by the Buyers of any Offered Securities is subject in
      all cases to the preparation, execution and delivery by the Company and
      the Buyers of a purchase agreement relating to such Offered Securities
      reasonably satisfactory in form and substance to the Buyers and their
      respective counsel.

                        (6) Any Offered Securities not acquired by the Buyers or
      other persons in accordance with Section 4(q)(iii)(4) above may not be
      issued, sold or exchanged until they are again offered to the Buyers under
      the procedures specified in this Agreement.

                  (iv) The restrictions contained in subsections (ii) and (iii)
of this Section 4(q) shall not apply in connection with the issuance of any
Excluded Securities (as defined in the Notes).

            (r) Stockholder Approval. The Company shall provide each stockholder
entitled to vote at a special or annual meeting of stockholders of the Company
(the "STOCKHOLDER MEETING"), which shall be promptly called and held not later
than November 21, 2005 (the

                                      -23-
<PAGE>

"STOCKHOLDER MEETING DEADLINE"), a proxy statement, substantially in the form
which has been previously reviewed by the Buyers and a counsel of their choice,
soliciting each such stockholder's affirmative vote at the Stockholder Meeting
for approval of resolutions providing for (i) the Company's issuance of all of
the Securities as described in the Transaction Documents in accordance with
applicable law and the rules and regulations of the Principal Market and (ii)
the increase in the Company's authorized capital by at least 10,000,000 shares
of Common Stock (such affirmative approval of the matters set forth in (i) and
(ii) of this Section 4(r) collectively being referred to herein as the
"STOCKHOLDER APPROVAL"), and the Company shall use its reasonable best efforts
to solicit its stockholders' approval of such resolutions (which reasonable
efforts shall include, in the Company's sole discretion, the requirement to hire
a reputable proxy solicitor) and use its reasonable best efforts to cause the
Board of Directors of the Company to recommend to the stockholders that they
approve such resolutions. The Company shall be obligated to seek to obtain the
Stockholder Approval by the Stockholder Meeting Deadline. If, despite the
Company's best efforts the Stockholder Approval is not obtained on or prior to
the Stockholder Meeting Deadline, the Company shall cause an additional
Stockholder Meeting to be held each calendar quarter thereafter until such
Stockholder Approval is obtained.

            (s) Voting Agreement. The Company shall use its reasonable best
efforts to effectuate the transactions contemplated by the Voting Agreement,
substantially in the form attached hereto as Exhibit H, executed by the Company
and each of Leigh S. Belden and Beltech, Inc. (the "VOTING AGREEMENT").

            (t) Sale of Alabama Building. Upon any sale, transfer or other
disposition of the Company's real property located in Alabama subject to the
Alabama Mortgage, the Company shall establish with a bank acceptable to the
Senior Agent (the "CASH COLLATERAL BANK") a deposit account (together with all
monies on deposit in such deposit account and all certificates and instruments,
if any, representing or evidencing such deposit account, the "CASH COLLATERAL
ACCOUNT") into which the Company shall place One Million Dollars ($1,000,000),
and shall cause the Cash Collateral Bank to enter to an account control
agreement with the Senior Agent, in a form reasonably acceptable to the Senior
Agent. The Cash Collateral Account shall at all times be under the dominion and
control of the Senior Agent. Upon the request of the Senior Agent, the Company
shall also execute and deliver such other customary agreements and instruments
necessary to grant the Buyers a first priority perfected security interest in
the Cash Collateral Account to secure the Notes. The Company agrees that it
shall not permit the Cash Collateral Account to be subject to any lien, pledge,
charge, security interest or other encumbrance other than as provided in the
immediately preceding sentence. The Cash Collateral Account will become
unrestricted when less than $4,000,000 in principal amount of Notes is
outstanding.

      5. REGISTER; TRANSFER AGENT INSTRUCTIONS.

            (a) Register. The Company shall maintain at its principal executive
offices (or such other office or agency of the Company as it may designate by
notice to each holder of Securities), a register for the Notes, the Warrants and
the Additional Investment Rights, in which the Company shall record the name and
address of the Person in whose name the Notes, the Warrants and Additional
Investment Rights have been issued (including the name and address of each
transferee), the principal amount of Notes held by such Person, the number of
Interest

                                      -24-
<PAGE>

Shares issuable pursuant to the terms of the Notes, Conversion Shares issuable
upon conversion of the Notes and Warrant Shares issuable upon exercise of the
Warrants held by such Person. The Company shall keep the register open and
available at all times during business hours for inspection of any Buyer or its
legal representatives.

            (b) Transfer Agent Instructions. The Company shall issue irrevocable
instructions to its transfer agent, and any subsequent transfer agent, to issue
certificates or credit shares to the applicable balance accounts at The
Depository Trust Company ("DTC"), registered in the name of each Buyer or its
respective nominee(s), for the Conversion Shares, the Interest Shares, if any,
and the Warrant Shares issued at the Closing or upon conversion of the Notes or
exercise of the Warrants in such amounts as specified from time to time by each
Buyer to the Company upon conversion of the Notes or exercise of the Warrants in
the form of Exhibit I attached hereto (the "IRREVOCABLE TRANSFER AGENT
INSTRUCTIONS"). The Company warrants that no instruction other than the
Irrevocable Transfer Agent Instructions referred to in this Section 5(b), and
stop transfer instructions to give effect to Section 2(h) hereof, will be given
by the Company to its transfer agent, and that the Securities shall otherwise be
freely transferable on the books and records of the Company as and to the extent
provided in this Agreement and the other Transaction Documents. If a Buyer
effects a sale, assignment or transfer of the Securities in accordance with
Section 2(g), the Company shall permit the transfer and shall promptly instruct
its transfer agent to issue one or more certificates or credit shares to the
applicable balance accounts at DTC in such name and in such denominations as
specified by such Buyer to effect such sale, transfer or assignment, unless such
transfer is prohibited by applicable law. In the event that such sale,
assignment or transfer involves Conversion Shares, Interest Shares or Warrant
Shares sold, assigned or transferred pursuant to an effective registration
statement or pursuant to Rule 144 with appropriate confirmation of this fact,
the transfer agent shall issue such Securities to the Buyer, assignee or
transferee, as the case may be, without any restrictive legend. The Company
acknowledges that a breach by it of its obligations hereunder will cause
irreparable harm to a Buyer. Accordingly, the Company acknowledges that the
remedy at law for a breach of its obligations under this Section 5(b) will be
inadequate and agrees, in the event of a breach or threatened breach by the
Company of the provisions of this Section 5(b), that a Buyer shall be entitled,
in addition to all other available remedies, to an order and/or injunction
restraining any breach and requiring immediate issuance and transfer, without
the necessity of showing economic loss and without any bond or other security
being required.

      6. COLLATERAL AGENT

            Portside Growth & Opportunity Fund is hereby appointed the
Collateral Agent hereunder and under the other Security Documents and each Buyer
hereby authorizes the Collateral Agent (and its officers, directors, employees
and agents) to take such action on such Buyer's behalf in accordance with the
terms hereof and thereof. The Collateral Agent shall not have, by reason hereof
or any of the other Security Documents, a fiduciary relationship in respect of
any Buyer. Neither the Collateral Agent nor any of its officers, directors,
employees and agents shall have any liability to any Buyer for any action taken
or omitted to be taken in connection hereof or any other Security Document
except to the extent caused by its own gross negligence or willful misconduct,
and each Buyer agrees to defend, protect, indemnify and hold harmless the
Collateral Agent and all of its officers, directors, employees and agents
(collectively, the "COLLATERAL INDEMNITEES") from and against any losses,
damages, liabilities,

                                      -25-
<PAGE>

obligations, penalties, actions, judgments, suits, fees, costs and expenses
(including, without limitation, reasonable attorneys' fees, costs and expenses)
incurred by such Collateral Indemnitee, whether direct, indirect or
consequential, arising from or in connection with the performance by such
Collateral Indemnitee of the duties and obligations of Collateral Agent pursuant
hereto or any of the Security Documents.

      7. CONDITIONS TO THE COMPANY'S OBLIGATION TO SELL.

            Closing Date. The obligation of the Company hereunder to issue and
sell the Notes, the related Warrants and the related Additional Investment
Rights to each Buyer at the Closing is subject to the satisfaction, at or before
the Closing Date, of each of the following conditions, provided that these
conditions are for the Company's sole benefit and may be waived by the Company
at any time in its sole discretion by providing each Buyer with prior written
notice thereof:

                  (i) Such Buyer shall have executed each of the Transaction
Documents to which it is a party and delivered the same to the Company.

                  (ii) Such Buyer and each other Buyer shall have delivered to
the Company the Purchase Price (less, in the case of Portside Growth &
Opportunity Fund, the amounts withheld pursuant to Section 4(g)) for the Notes
and the related Warrants and Additional Investment Rights being purchased by
such Buyer at the Closing by wire transfer of immediately available funds
pursuant to the wire instructions provided by the Company.

                  (iii) The representations and warranties of such Buyer shall
be true and correct in all material respects as of the date when made and as of
the Closing Date as though made at that time (except for representations and
warranties that speak as of a specific date), and such Buyer shall have
performed, satisfied and complied in all material respects with the covenants,
agreements and conditions required by this Agreement to be performed, satisfied
or complied with by such Buyer at or prior to the Closing Date.

      8. CONDITIONS TO EACH BUYER'S OBLIGATION TO PURCHASE.

            (a) Closing Date. The obligation of each Buyer hereunder to purchase
the Notes and the related Warrants and Additional Investment Rights at the
Closing is subject to the satisfaction, at or before the Closing Date, of each
of the following conditions, provided that these conditions are for each Buyer's
sole benefit and may be waived by such Buyer at any time in its sole discretion
by providing the Company with prior written notice thereof:

                  (i) The Company and, to the extent it is a party thereto, each
of its Existing Subsidiaries, shall have duly executed and delivered to such
Buyer: (A) the Initial Notes (in such principal amounts as such Buyer shall
request) being purchased by such Buyer at the Closing pursuant to this
Agreement, (B) the Warrants (in such amounts as such Buyer shall request) being
purchased by such Buyer at the Closing pursuant to this Agreement; (C) the
Additional Investment Rights (in such amounts as such Buyer shall request) being
purchased by such Buyer at the Closing pursuant to this Agreement: (D) the
Pledge and Security Agreement; (E) the Guaranty, and (F) each of the other
Transaction Documents.

                                      -26-
<PAGE>

                  (ii) The Voting Agreement shall have been executed and
delivered to such Buyer by the Company and each of Leigh S. Belden and Beltech,
Inc.

                  (iii) Such Buyer shall have received the opinion of Cooley
Godward LLP, the Company's outside counsel, dated as of the Closing Date, in
substantially the form of Exhibit J attached hereto.

                  (iv) The Company shall have delivered to such Buyer a copy of
the Irrevocable Transfer Agent Instructions, in the form of Exhibit I attached
hereto, which instructions shall have been delivered to and acknowledged in
writing by the Company's transfer agent.

                  (v) The Company shall have delivered to such Buyer a
certificate evidencing the formation and good standing of the Company and
Verilink Europe Limited in such entity's jurisdiction of formation issued by the
Secretary of State (or comparable office) of such jurisdiction, as of a date
within 10 days of the Closing Date.

                  (vi) The Company shall have delivered to such Buyer a
certificate evidencing the Company's qualification as a foreign corporation and
good standing issued by the Secretary of State (or comparable office) of each
jurisdiction in which the Company conducts business and is required to qualify
to do business as a foreign corporation, where such failure to so qualify would
have a Material Adverse Effect on the Company or its Subsidiaries, as of a date
within 10 days of the Closing Date.

                  (vii) The Company shall have delivered to such Buyer a
certified copy of the Certificate of Incorporation as certified by the Secretary
of State of the State of Delaware within ten (10) days of the Closing Date.

                  (viii) The Company shall have delivered to such Buyer a
certificate, executed by the Secretary of the Company and dated as of the
Closing Date, as to (i) the resolutions consistent with Section 3(b) as adopted
by the Company's Board of Directors in a form reasonably acceptable to such
Buyer, (ii) the Certificate of Incorporation and (iii) the Bylaws, each as in
effect at the Closing, in the form attached hereto as Exhibit K.

                  (ix) The representations and warranties of the Company shall
be true and correct in all material respects (except for those representations
and warranties that are qualified by materiality or Material Adverse Effect,
which shall be true and correct in all respects) as of the Closing Date as
though made at that time (except for representations and warranties that speak
as of a specific date) and the Company shall have performed, satisfied and
complied in all material respects with the covenants, agreements and conditions
required by the Transaction Documents to be performed, satisfied or complied
with by the Company at or prior to the Closing Date. Such Buyer shall have
received a certificate, executed by the Chief Executive Officer of the Company,
dated as of the Closing Date, to the foregoing effect and as to such other
matters as may be reasonably requested by such Buyer in the form attached hereto
as Exhibit L.

                                      -27-
<PAGE>

                  (x) The Company shall have delivered to such Buyer a letter
from the Company's transfer agent certifying the number of shares of Common
Stock outstanding as of a date within five days of the Closing Date.

                  (xi) The Common Stock (i) shall be designated for quotation or
listed on the Principal Market and (ii) shall not have been suspended, as of the
Closing Date, by the SEC or the Principal Market from trading on the Principal
Market nor shall suspension by the SEC or the Principal Market have been
threatened, as of the Closing Date, either (A) in writing by the SEC or the
Principal Market or (B) by falling below the minimum listing maintenance
requirements of the Principal Market.

                  (xii) The Company shall have obtained all governmental,
regulatory or third party consents and approvals, if any, necessary for the sale
of the Securities. Without limiting the generality of the foregoing, the Company
shall also have obtained the consent or waiver of Regions Bank, with respect to
the granting of junior real estate mortgage to secure the Notes, on its building
and property in Cummings Research Park at 950 Explorer Boulevard, Huntsville,
Alabama to the Senior Agent, which shall be junior in priority to Regions Bank's
existing mortgages, with such other agreements as the Buyers shall reasonably
require to ensure that the Buyers enjoy full rights with respect to the
Collateral, evidence of which shall have been provided to the Buyers.

                  (xiii) In accordance with the terms of the Security Documents,
the Company and the shall have delivered to the Agent (as defined in the Pledge
and Security Agreement) certificates, if issued, representing the shares of
capital stock of its Subsidiaries pledged under the Pledge and Security
Agreement, along with duly executed blank stock powers.

                  (xiv) A pay-off letter in form and substance satisfactory to
the Senior Agent from RBC Centura Bank.

                  (xv) The Company shall have delivered to such Buyer such other
documents relating to the transactions contemplated by this Agreement as such
Buyer or its counsel may reasonably request.

            (b) Conditions Subsequent to the Closing. The Company shall deliver
to the Buyers not later than thirty (30) days following the Closing Date:

                  (i) such depository account, blocked account, lockbox account
and similar agreements and other documents, each in form and substance
reasonably satisfactory to the Senior Agent, as the Senior Agent may request
with respect to the cash management system of the Company and the Existing
Subsidiaries.

                  (ii) a mortgage, in form and substance reasonably satisfactory
to the Buyers, covering all of the Company's right, title and interest in and to
the real property located in the Cummings Research Park West in Huntsville,
Madison County, Alabama, together with all improvements located thereon
(collectively, the "PROPERTY"), duly executed by the Company (the "NEW
MORTGAGE"), subject only to the items set forth on Schedule 8(b), together with,
at the request of the Buyers, a current title search report, a title insurance
policy, evidence of insurance, a current survey of the Property, and a current
appraisal of the Property;

                                      -28-
<PAGE>

                  (iii) UCC-1 Financing Statements naming the Buyers as secured
parties covering all fixtures, furniture, furnishings, equipment, machinery,
goods, general intangibles, money, insurance proceeds, contract rights, option
rights, inventory, all refundable, returnable or reimbursable fees, deposits or
other funds or evidences of credit or indebtedness deposited by or on behalf of
the Company with any governmental agencies, boards, corporations, providers of
utility services, public or private, including all refundable, returnable or
reimbursable tap fees, utility deposits, commitment fees and development costs,
and all other personal property of any kind or character, which are now or
hereafter located or to be located upon, within or about the Property, or which
are or may be used in or related to the planning, development, financing or
operation of the Property, together with all accessories, replacements and
substitutions thereto or therefor and the proceeds thereof;

                  (iv) all required consents to or approvals of the execution
and delivery by the Company of the New Mortgage, including, without limitation,
the written consent of (i) Regions Bank, and (ii) The Industrial Development
Board of the City of Huntsville;

                  (v) the opinion of local Alabama counsel for the Company,
addressed to each Buyer, with respect to the enforceability and perfection of
the New Mortgage and any related fixture filings in form and substance
reasonably satisfactory to the Buyers;

                  (vi) the opinion of counsel to the Company, addressed to each
Buyer, as to due authorization, execution and delivery of the New Mortgage by
the Company in form and substance reasonably satisfactory to the Buyers; and

                  (vii) any other instruments, documents or information that the
Buyers may reasonably deem necessary to create a valid second and subsisting
lien on the Property, each in scope, form and substance reasonably satisfactory
to the Buyers.

            (c) Good Standing. The Company shall deliver to the Buyers not later
than fifteen (15) days following the Closing Date: (i) a certificate evidencing
the incorporation and good standing of Larscom Incorporated ("LARSCOM") issued
by the Secretary of State of the State of Delaware as of a date within 10 days
of the Closing Date and (ii) a certificate evidencing the qualification of
Larscom as a foreign corporation and good standing issued by the Secretary of
State (or comparable office) of each jurisdiction in which Larscom conducts
business and is required to qualify to do business as a foreign corporation,
where such failure to so qualify would have a Material Adverse Effect on
Larscom, as of a date within 10 days of the Closing Date.

            (d) UCC-3. Promptly, and in any event, within three (3) days after
the Closing Date, the Company shall deliver to the Senior Agent evidence that
the UCC-3s terminating all UCC-1s filed with resect to the security interests in
favor of RBC Centura Bank have been duly submitted for filing.

            (e) Copyrights. Promptly, and in any event, within three (3) days
after the Closing Date, the Company shall deliver to the Senior Agent the
necessary assignment documentation such that the Senior Agent may record the
grant of security interest with respect to registered Copyrights (as defined in
the Pledge and Security Agreement) in the United States Copyright Office.

      9. TERMINATION.

            In the event that the Closing shall not have occurred with respect
to a Buyer on or before five (5) Business Days from the date hereof due to the
Company's or such Buyer's failure to satisfy the conditions set forth in
Sections 6 and 7 above (and the nonbreaching party's failure

                                      -29-
<PAGE>

to waive such unsatisfied condition(s)), the nonbreaching party shall have the
option to terminate this Agreement with respect to such breaching party at the
close of business on such date without liability of any party to any other
party; provided, however, this if this Agreement is terminated pursuant to this
Section 9, the Company shall remain obligated to reimburse the non-breaching
Buyers for the expenses described in Section 4(g) above.

      10. MISCELLANEOUS.

            (a) Governing Law; Jurisdiction; Jury Trial. All questions
concerning the construction, validity, enforcement and interpretation of this
Agreement shall be governed by the internal laws of the State of New York,
without giving effect to any choice of law or conflict of law provision or rule
(whether of the State of New York or any other jurisdictions) that would cause
the application of the laws of any jurisdictions other than the State of New
York. Each party hereby irrevocably submits to the exclusive jurisdiction of the
state and federal courts sitting in The City of New York, Borough of Manhattan,
for the adjudication of any dispute hereunder or in connection herewith or with
any transaction contemplated hereby or discussed herein, and hereby irrevocably
waives, and agrees not to assert in any suit, action or proceeding, any claim
that it is not personally subject to the jurisdiction of any such court, that
such suit, action or proceeding is brought in an inconvenient forum or that the
venue of such suit, action or proceeding is improper. Each party hereby
irrevocably waives personal service of process and consents to process being
served in any such suit, action or proceeding by mailing a copy thereof to such
party at the address for such notices to it under this Agreement and agrees that
such service shall constitute good and sufficient service of process and notice
thereof. Nothing contained herein shall be deemed to limit in any way any right
to serve process in any manner permitted by law. EACH PARTY HEREBY IRREVOCABLY
WAIVES ANY RIGHT IT MAY HAVE, AND AGREES NOT TO REQUEST, A JURY TRIAL FOR THE
ADJUDICATION OF ANY DISPUTE HEREUNDER OR IN CONNECTION WITH OR ARISING OUT OF
THIS AGREEMENT OR ANY TRANSACTION CONTEMPLATED HEREBY.

            (b) Counterparts. This Agreement may be executed in two or more
identical counterparts, all of which shall be considered one and the same
agreement and shall become effective when counterparts have been signed by each
party and delivered to the other party; provided that a facsimile signature
shall be considered due execution and shall be binding upon the signatory
thereto with the same force and effect as if the signature were an original, not
a facsimile signature.

            (c) Headings. The headings of this Agreement are for convenience of
reference and shall not form part of, or affect the interpretation of, this
Agreement.

            (d) Severability. If any provision of this Agreement shall be
invalid or unenforceable in any jurisdiction, such invalidity or
unenforceability shall not affect the validity or enforceability of the
remainder of this Agreement in that jurisdiction or the validity or
enforceability of any provision of this Agreement in any other jurisdiction.

            (e) Entire Agreement; Amendments. This Agreement supersedes all
other prior oral or written agreements between the Buyers, the Company, their
affiliates and Persons acting

                                      -30-
<PAGE>

on their behalf with respect to the matters discussed herein, and this Agreement
and the instruments referenced herein contain the entire understanding of the
parties with respect to the matters covered herein and therein and, except as
specifically set forth herein or therein, neither the Company nor any Buyer
makes any representation, warranty, covenant or undertaking with respect to such
matters. No provision of this Agreement may be amended other than by an
instrument in writing signed by the Company and the holders of at least a
majority of the aggregate number of Registrable Securities issued and issuable
hereunder, and any amendment to this Agreement made in conformity with the
provisions of this Section 10(e) shall be binding on all Buyers and holders of
Securities, as applicable. No provision hereof may be waived other than by an
instrument in writing signed by the party against whom enforcement is sought. No
such amendment shall be effective to the extent that it applies to less than all
of the holders of the applicable Securities then outstanding. No consideration
shall be offered or paid to any Person to amend or consent to a waiver or
modification of any provision of any of the Transaction Documents unless the
same consideration also is offered to all of the parties to the Transaction
Documents, holders of Notes, holders of the Warrants or holders of the
Additional Investment Rights, as the case may be. The Company has not, directly
or indirectly, made any agreements with any Buyers relating to the terms or
conditions of the transactions contemplated by the Transaction Documents except
as set forth in the Transaction Documents.

            (f) Notices. Any notices, consents, waivers or other communications
required or permitted to be given under the terms of this Agreement must be in
writing and will be deemed to have been delivered: (i) upon receipt, when
delivered personally; (ii) upon receipt, when sent by facsimile (provided
confirmation of transmission is mechanically or electronically generated and
kept on file by the sending party); or (iii) one Business Day after deposit with
an overnight courier service, in each case properly addressed to the party to
receive the same. The addresses and facsimile numbers for such communications
shall be:

                  If to the Company:

                         Verilink Corporation
                         11551 E. Arapahoe Rd., Suite 150
                         Centennial, Colorado 80112
                         Telephone: (303) 968-3000
                         Facsimile: (303) 968-3005
                         Attention: Chief Financial Officer

                         Copy (which shall not constitute valid notice) to:

                         Cooley Godward LLP
                         380 Interlocken Crescent, Suite 900
                         Broomfield, CO 80021
                         Telephone: (720) 566-4000
                         Facsimile: (720) 566-4099
                         Attention: Brent D. Fassett, Esq.

                                      -31-
<PAGE>

                  If to the Transfer Agent:

                         American Stock Transfer & Trust Company
                         Operations Center
                         6201 15th Avenue
                         Brooklyn, New York 11219
                         Telephone: (718) 921-8145
                         Facsimile: (718) 921-8116
                         Attention: Office of General Counsel

If to a Buyer, to its address and facsimile number set forth on the Schedule of
Buyers, with copies to such Buyer's representatives as set forth on the Schedule
of Buyers,

      with a copy (for informational purposes only) to:

            Schulte Roth & Zabel LLP
            919 Third Avenue
            New York, New York  10022
            Telephone: (212) 756-2000
            Facsimile: (212) 593-5955
            Attention: Eleazer N. Klein, Esq.

or to such other address and/or facsimile number and/or to the attention of such
other Person as the recipient party has specified by written notice given to
each other party five (5) days prior to the effectiveness of such change.
Written confirmation of receipt (A) given by the recipient of such notice,
consent, waiver or other communication, (B) mechanically or electronically
generated by the sender's facsimile machine containing the time, date, recipient
facsimile number and an image of the first page of such transmission or (C)
provided by an overnight courier service shall be rebuttable evidence of
personal service, receipt by facsimile or receipt from an overnight courier
service in accordance with clause (i), (ii) or (iii) above, respectively.

            (g) Successors and Assigns. This Agreement shall be binding upon and
inure to the benefit of the parties and their respective successors and assigns,
including any purchasers of the Notes, the Warrants or the Additional Investment
Rights. The Company shall not assign this Agreement or any rights or obligations
hereunder without the prior written consent of the holders of at least a
majority of the aggregate number of Registrable Securities issued and issuable
hereunder, including by way of a Fundamental Transaction (unless the Company is
in compliance with the applicable provisions governing Fundamental Transactions
set forth in the Notes, the Warrants and the Additional Investment Rights). A
Buyer may assign some or all of its rights hereunder without the consent of the
Company in connection with a transfer by such Buyer of any of the Securities, in
which event such assignee shall be deemed to be a Buyer hereunder with respect
to such assigned rights.

            (h) No Third Party Beneficiaries. This Agreement is intended for the
benefit of the parties hereto and their respective permitted successors and
assigns, and is not for the benefit of, nor may any provision hereof be enforced
by, any other Person.

                                      -32-
<PAGE>

            (i) Survival. Unless this Agreement is terminated under Section 9,
the representations and warranties of the Company and the Buyers contained in
Sections 2 and 3 and the agreements and covenants set forth in Sections 4, 5 and
9 shall survive the Closing. Each Buyer shall be responsible only for its own
representations, warranties, agreements and covenants hereunder.

            (j) Further Assurances. Each party shall do and perform, or cause to
be done and performed, all such further acts and things, and shall execute and
deliver all such other agreements, certificates, instruments and documents, as
any other party may reasonably request in order to carry out the intent and
accomplish the purposes of this Agreement and the consummation of the
transactions contemplated hereby.

            (k) Indemnification. In consideration of each Buyer's execution and
delivery of the Transaction Documents and acquiring the Securities thereunder
and in addition to all of the Company's other obligations under the Transaction
Documents, the Company shall defend, protect, indemnify and hold harmless each
Buyer and each other holder of the Securities and all of their stockholders,
partners, members, officers, directors, employees and direct or indirect
investors and any of the foregoing Persons' agents or other representatives
(including, without limitation, those retained in connection with the
transactions contemplated by this Agreement) (collectively, the "INDEMNITEES")
from and against any and all actions, causes of action, suits, claims, losses,
costs, penalties, fees, liabilities and damages, and expenses in connection
therewith (irrespective of whether any such Indemnitee is a party to the action
for which indemnification hereunder is sought), and including reasonable
attorneys' fees and disbursements (the "INDEMNIFIED LIABILITIES"), incurred by
any Indemnitee as a result of, or arising out of, or relating to (a) any
material inaccuracy in any representation or warranty made by the Company in the
Transaction Documents or any inaccuracy in any representation or warranty in the
Transaction Documents that is qualified by materiality or Material Adverse
Effect, (b) any breach of any covenant, agreement or obligation of the Company
contained in the Transaction Documents or (c) any cause of action, suit or claim
brought or made against such Indemnitee by a third party (including for these
purposes a derivative action brought on behalf of the Company) and arising out
of or resulting from (i) the execution, delivery, performance or enforcement of
the Transaction Documents, (ii) any transaction financed or to be financed in
whole or in part, directly or indirectly, with the proceeds of the issuance of
the Securities, or (iii) the status of such Buyer or holder of the Securities as
an investor in the Company pursuant to the transactions contemplated by the
Transaction Documents; provided that indemnification pursuant to this clause
(iii) shall not be available to the extent arising primarily from such Buyer's
fraud, gross negligence, willful misconduct or breach of representation,
warranty or covenant made by such Buyer in any Transaction Document. To the
extent that the foregoing undertaking by the Company may be unenforceable for
any reason, the Company shall make the maximum contribution to the payment and
satisfaction of each of the Indemnified Liabilities that is permissible under
applicable law. Except as otherwise set forth herein, the mechanics and
procedures with respect to the rights and obligations under this Section 10(k)
shall be the same as those set forth in Section 6 of the Registration Rights
Agreement.

            (l) No Strict Construction. The language used in this Agreement will
be deemed to be the language chosen by the parties to express their mutual
intent, and no rules of strict construction will be applied against any party.

                                      -33-
<PAGE>

            (m) Remedies. Each Buyer and each holder of the Securities shall
have all rights and remedies set forth in the Transaction Documents and all
rights and remedies which such holders have been granted at any time under any
other agreement or contract and all of the rights which such holders have under
any law. Any Person having any rights under any provision of this Agreement
shall be entitled to enforce such rights specifically (without posting a bond or
other security), to recover damages by reason of any breach of any provision of
this Agreement and to exercise all other rights granted by law. Furthermore, the
Company recognizes that in the event that it fails to perform, observe, or
discharge any or all of its obligations under the Transaction Documents, any
remedy at law may prove to be inadequate relief to the Buyers. The Company
therefore agrees that the Buyers shall be entitled to seek temporary and
permanent injunctive relief in any such case without the necessity of proving
actual damages and without posting a bond or other security.

            (n) Rescission and Withdrawal Right. Notwithstanding anything to the
contrary contained in (and without limiting any similar provisions of) the
Transaction Documents, whenever any Buyer exercises a right, election, demand or
option under a Transaction Document and the Company does not timely perform its
related obligations within the periods therein provided, then such Buyer may
rescind or withdraw, in its sole discretion from time to time upon written
notice to the Company, any relevant notice, demand or election in whole or in
part without prejudice to its future actions and rights.

            (o) Payment Set Aside. To the extent that the Company makes a
payment or payments to the Buyers hereunder or pursuant to any of the other
Transaction Documents or the Buyers enforce or exercise their rights hereunder
or thereunder, and such payment or payments or the proceeds of such enforcement
or exercise or any part thereof are subsequently invalidated, declared to be
fraudulent or preferential, set aside, recovered from, disgorged by or are
required to be refunded, repaid or otherwise restored to the Company, a trustee,
receiver or any other Person under any law (including, without limitation, any
bankruptcy law, foreign, state or federal law, common law or equitable cause of
action), then to the extent of any such restoration the obligation or part
thereof originally intended to be satisfied shall be revived and continued in
full force and effect as if such payment had not been made or such enforcement
or setoff had not occurred.

            (p) Independent Nature of Buyers' Obligations and Rights. The
obligations of each Buyer under any Transaction Document are several and not
joint with the obligations of any other Buyer, and no Buyer shall be responsible
in any way for the performance of the obligations of any other Buyer under any
Transaction Document. Nothing contained herein or in any other Transaction
Document, and no action taken by any Buyer pursuant hereto or thereto, shall be
deemed to constitute the Buyers as a partnership, an association, a joint
venture or any other kind of entity, or create a presumption that the Buyers are
in any way acting in concert or as a group with respect to such obligations or
the transactions contemplated by the Transaction Documents and the Company
acknowledges that the Buyers are not acting in concert or as a group with
respect to such obligations or the transactions contemplated by the Transaction
Documents. Each Buyer confirms that it has independently participated in the
negotiation of the transaction contemplated hereby with the advice of its own
counsel and advisors. Each Buyer shall be entitled to independently protect and
enforce its rights, including, without limitation, the rights arising out of
this Agreement or out of any other Transaction Documents, and it shall not be

                                      -34-
<PAGE>

necessary for any other Buyer to be joined as an additional party in any
proceeding for such purpose.

                            [SIGNATURE PAGE FOLLOWS]

                                      -35-
<PAGE>

      IN WITNESS WHEREOF, each Buyer and the Company have caused their
respective signature page to this Securities Purchase Agreement to be duly
executed as of the date first written above.

                                              COMPANY:

                                              VERILINK CORPORATION

                                              By: /s/ Leigh S. Belden
                                                 -------------------------------
                                                  Name:  Leigh S. Belden
                                                  Title: President and CEO

                [Signature Page to Securities Purchase Agreement]

<PAGE>

      IN WITNESS WHEREOF, each Buyer and the Company have caused their
respective signature page to this Securities Purchase Agreement to be duly
executed as of the date first written above.

                                              BUYER:

                                              PORTSIDE GROWTH &
                                              OPPORTUNITY FUND

                                              By: /s/ Jeffrey Smith
                                                 -------------------------------
                                                  Name:  Jeffrey Smith
                                                  Title: Authorized Signatory

                [Signature Page to Securities Purchase Agreement]

<PAGE>

      IN WITNESS WHEREOF, each Buyer and the Company have caused their
respective signature page to this Securities Purchase Agreement to be duly
executed as of the date first written above.

                                              BUYER:

                                              SMITHFIELD FIDUCIARY LLC

                                              By: /s/ Adam J. Chill
                                                 -------------------------------
                                                  Name: Adam J. Chill
                                                  Title: Authorized Signatory

                [Signature Page to Securities Purchase Agreement]

<PAGE>

      IN WITNESS WHEREOF, each Buyer and the Company have caused their
respective signature page to this Securities Purchase Agreement to be duly
executed as of the date first written above.

                                              BUYER:

                                              D.B. ZWIRN SPECIAL OPPORTUNITIES
                                              FUND, L.P.

                                              By: D.B. Zwirn and Co., L.P.

                                              By: /s/ David Proshan
                                                 -------------------------------
                                                  Name:  David Proshan
                                                  Title: General Counsel

                [Signature Page to Securities Purchase Agreement]

<PAGE>

      IN WITNESS WHEREOF, each Buyer and the Company have caused their
respective signature page to this Securities Purchase Agreement to be duly
executed as of the date first written above.

                                              BUYER:

                                              PROVIDENT PREMIER MASTER
                                              FUND, LTD.

                                              By: /s/ Steven W. Winters
                                                 -------------------------------
                                                  Name:  Steven W. Winters
                                                  Title: Attorney-In-Fact

                [Signature Page to Securities Purchase Agreement]

<PAGE>

      IN WITNESS WHEREOF, each Buyer and the Company have caused their
respective signature page to this Securities Purchase Agreement to be duly
executed as of the date first written above.

                                           BUYER:

                                           LANGLEY PARTNERS, L.P.

                                           By: Langley Capital, LLC, its General
                                                Partner

                                           By: /s/ Jeffrey Thorp
                                              --------------------------------
                                                Name: Jeffrey Thorp
                                                Title: Managing Member

                [Signature Page to Securities Purchase Agreement]

<PAGE>

      IN WITNESS WHEREOF, each Buyer and the Company have caused their
respective signature page to this Securities Purchase Agreement to be duly
executed as of the date first written above.

                                             BUYER:

                                             JGB CAPITAL L.P.

                                             By: JGB Management Inc., as General
                                                  Partner

                                             By: /s/ Brett Cohen
                                                -------------------------------
                                                 Name: Brett Cohen
                                                 Title: President

                [Signature Page to Securities Purchase Agreement]
<PAGE>

                               SCHEDULE OF BUYERS

<TABLE>
<CAPTION>
        (1)                          (2)                       (3)             (4)             (5)            (6)

                                                                                             MAXIMUM
                                                                                            AGGREGATE
                                                            AGGREGATE                       PRINCIPAL
                                                            PRINCIPAL                        AMOUNT OF
                                  ADDRESS AND               AMOUNT OF        NUMBER OF      ADDITIONAL
        BUYER                  FACSIMILE NUMBER           INITIAL NOTES   WARRANT SHARES      NOTES      PURCHASE PRICE
--------------------  ----------------------------------  -------------   --------------    ----------   --------------
<S>                   <C>                                 <C>             <C>              <C>           <C>
PORTSIDE GROWTH &     c/o Ramius Capital Group, L.L.C.      $4,000,000        332,226      $2,000,000      $4,000,000
OPPORTUNITY FUND      666 Third Avenue, 26th Floor
                      New York, New York 10017
                      Attention: Jeffrey Smith
                                 Michael Neidell
                      Facsimile: (212) 845-7999
                      Telephone: (212) 845-7955
                      Residence: Cayman Islands

SMITHFIELD FIDUCIARY  c/o Highbridge Capital Management,    $1,000,000         83,056      $  500,000      $1,000,000
LLC                   LLC
                      9 West 57th Street, 27th Floor
                      New York, New York  10019
                      Attention: Ari J. Storch
                                  Adam J. Chill
                      Facsimile: (212) 751-0755
                      Telephone: (212) 287-4720
                      Residence: Cayman Islands

D.B. ZWIRN SPECIAL    D.B. Zwirn & Co., L.P.                $1,000,000         83,056      $  500,000      $1,000,000
OPPORTUNITIES FUND,   745 Fifth Ave.
L.P.                  18th Floor
                      New York, New York
                      10151
                      Attention: Daniel B. Zwirn
                                 Perry A. Gruss
                      Telephone: 646-720-9101
                      Facsimile: 646-344-4743
                      Residence: Delaware

<CAPTION>
        (1)                           (7)                          (8)

                                                                QUALIFIED
                         LEGAL REPRESENTATIVE'S ADDRESS       INSTITUTIONAL
        BUYER                 AND FACSIMILE NUMBER                BUYER
--------------------    -------------------------------       -------------
<S>                     <C>                                   <C>
PORTSIDE GROWTH &       Schulte Roth & Zabel LLP                  Yes
OPPORTUNITY FUND        919 Third Avenue
                        New York, New York 10022
                        Attention: Eleazer Klein, Esq.
                        Facsimile: (212) 593-5955
                        Telephone: (212) 756-2376

SMITHFIELD FIDUCIARY                                              Yes
LLC

ZWIRN SPECIAL                                                     Yes
OPPORTUNITIES FUND,
L.P.
</TABLE>

<PAGE>

<TABLE>
<S>                   <C>                                   <C>                <C>          <C>            <C>           <C>
PROVIDENT PREMIER     c/o Gemini Investment Strategies,     $1,000,000         83,056       $  500,000     $1,000,000    Yes
                      LLC
MASTER                35 Waterview Boulevard
FUND, LTD.            Parsippany, NJ 07054
                      Attention: Steven Winters
                      Facsimile: (973) 404-1360
                      Telephone: (973) 404-1350
                      Residence: Cayman Islands

LANGLEY PARTNERS,     c/o Langley Capital, LLC              $1,000,000         83,056       $  500,000     $1,000,000    Yes
 L.P.                 535 Madison Avenue, 7th Floor
                      New York, NY 10022
                      Attention: Jeffrey Thorp
                      Facsimile: (212) 208-2971
                      Telephone: (212) 850-7528
                      Residence: Delaware

JGB CAPITAL L.P.      660 Madison, 21st floor               $2,000,000        166,113       $1,000,000     $2,000,000    No
                      New York, NY 10021
                      Attention: Brett Cohen
                      Facsimile: (212) 253-4093
                      Telephone: (212) 355-5771
                      Residence: Delaware
</TABLE>

<PAGE>

                                    EXHIBITS

Exhibit A  Form of Initial Notes
Exhibit B  Form of Warrants
Exhibit C  Form of Additional Investment Rights
Exhibit D  Form of Additional Notes
Exhibit E  Registration Rights Agreement
Exhibit F  Form of Pledge and Security Agreement
Exhibit G  Form of Guarantee
Exhibit H  Form of Voting Agreement
Exhibit I  Irrevocable Transfer Agent Instructions
Exhibit J  Form of Outside Company Counsel Opinion
Exhibit K  Form of Secretary's Certificate
Exhibit L  Form of Officer's Certificate<PAGE>

                                                                   EXHIBIT 10.20

                                [FORM OF WARRANT]

NEITHER THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE
NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE EXERCISEABLE HAVE BEEN
REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE "SECURITIES ACT"),
OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE,
SOLD, TRANSFERRED OR ASSIGNED IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION
STATEMENT FOR THE SECURITIES UNDER THE SECURITIES ACT, (B) AN OPINION OF
COUNSEL, REASONABLY ACCEPTABLE TO THE COMPANY, THAT REGISTRATION IS NOT REQUIRED
UNDER SAID ACT OR (C) REASONABLE ASSURANCE HAVING BEEN PROVIDED TO THE COMPANY
THAT SUCH OFFER, SALE, ASSIGNMENT OR TRANSFER IS BEING MADE PURSUANT TO RULE 144
OR RULE 144A UNDER SAID ACT. NOTWITHSTANDING THE FOREGOING, THE SECURITIES MAY
BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT OR OTHER LOAN OR
FINANCING ARRANGEMENT SECURED BY THE SECURITIES.

                              VERILINK CORPORATION

                        WARRANT TO PURCHASE COMMON STOCK

Warrant No.:___________
Number of Shares of Common Stock:_____________
Date of Issuance: March 21, 2005 ("ISSUANCE DATE")

            Verilink Corporation, a Delaware corporation (the "COMPANY"), hereby
certifies that, for good and valuable consideration, the receipt and sufficiency
of which are hereby acknowledged, [BUYERS], the registered holder hereof or its
permitted assigns (the "HOLDER"), is entitled, subject to the terms set forth
below, to purchase from the Company, at the Exercise Price (as defined below)
then in effect, upon surrender of this Warrant to Purchase Common Stock
(including any Warrants to Purchase Common Stock issued in exchange, transfer or
replacement hereof, the "WARRANT"), at any time or times on or after September
21, 2005 but not after 11:59 p.m., New York Time, on the Expiration Date (as
defined below), ______________ (_____________)(1) fully paid nonassessable
shares of Common Stock (as defined below) (the "WARRANT SHARES"). Except as
otherwise defined herein, capitalized terms in this Warrant shall have the
meanings set forth in Section 15. This Warrant is one of the Warrants to
Purchase Common Stock (the "SPA WARRANTS") issued pursuant to Section 1 of that
certain Securities Purchase Agreement, dated as of March 20, 2005 (the
"SUBSCRIPTION DATE"), by and among the Company and the investors (the "BUYERS")
referred to therein (the "SECURITIES PURCHASE AGREEMENT").

-----------------------
(1) Insert number of shares equal to (x) 25% of the principal amount of Initial
Notes issued to the Holder pursuant to the Securities Purchase Agreement divided
by (y) $3.01.

<PAGE>

            1. EXERCISE OF WARRANT.

                  (a) Mechanics of Exercise. Subject to the terms and conditions
hereof (including, without limitation, the limitations set forth in Section
1(f)), this Warrant may be exercised by the Holder on any day on or after
September 21, 2005 in whole or in part, by (i) delivery of a written notice, in
the form attached hereto as Exhibit A (the "EXERCISE NOTICE"), of the Holder's
election to exercise this Warrant, (ii) (A) payment to the Company of an amount
equal to the applicable Exercise Price multiplied by the number of Warrant
Shares as to which this Warrant is being exercised (the "AGGREGATE EXERCISE
PRICE") in cash or wire transfer of immediately available funds or (B) by
notifying the Company that this Warrant is being exercised pursuant to a
Cashless Exercise (as defined in Section 1(d)). The Holder shall not be required
to deliver the original Warrant in order to effect the exercise hereunder.
Execution and delivery of the Exercise Notice with respect to less than all of
the Warrant Shares shall have the same effect as cancellation of the original
Warrant and issuance of a new Warrant evidencing the right to purchase the
remaining number of Warrant Shares. On or before the first Business Day
following the date on which the Company has received each of the Exercise Notice
and the Aggregate Exercise Price (or notice of a Cashless Exercise) (the
"EXERCISE DELIVERY DOCUMENTS"), the Company shall transmit by facsimile an
acknowledgment of confirmation of receipt of the Exercise Delivery Documents to
the Holder and the Company's transfer agent (the "TRANSFER AGENT"). On or before
the third Business Day following the date on which the Company has received all
of the Exercise Delivery Documents (the "SHARE DELIVERY DATE"), the Company
shall (X) provided that the Transfer Agent is participating in The Depository
Trust Company ("DTC") Fast Automated Securities Transfer Program and such action
is not prohibited by applicable law or regulation or any applicable policy of
DTC, upon the request of the Holder, credit such aggregate number of shares of
Common Stock to which the Holder is entitled pursuant to such exercise to the
Holder's or its designee's balance account with DTC through its Deposit
Withdrawal Agent Commission system, or (Y) if the foregoing shall not apply,
issue and dispatch by overnight courier to the address as specified in the
Exercise Notice, a certificate, registered in the Company's share register in
the name of the Holder or its designee, for the number of shares of Common Stock
to which the Holder is entitled pursuant to such exercise. Upon delivery of the
Exercise Delivery Documents, the Holder shall be deemed for all corporate
purposes to have become the holder of record of the Warrant Shares with respect
to which this Warrant has been exercised, irrespective of the date of delivery
of the certificates evidencing such Warrant Shares. If this Warrant is delivered
to the Company in connection with any exercise pursuant to this Section 1(a) and
the number of Warrant Shares represented by this Warrant submitted for exercise
is greater than the number of Warrant Shares being acquired upon an exercise,
then the Company shall as soon as practicable and in no event later than five
Business Days after the Share Delivery Date and at its own expense, issue a new
Warrant (in accordance with Section 7(d)) representing the right to purchase the
number of Warrant Shares purchasable immediately prior to such exercise under
this Warrant, less the number of Warrant Shares with respect to which this
Warrant is exercised. No fractional shares of Common Stock are to be issued upon
the exercise of this Warrant, but rather the number of shares of Common Stock to
be issued shall be rounded up to the nearest whole number. The Company shall pay
any and all taxes which may be payable with respect to the issuance and delivery
of Warrant Shares upon exercise of this Warrant; provided that the Company shall
not be required to pay any tax that may be payable in respect of any issuance
and delivery of Warrant Shares to any Person other than the Holder or with
respect to any income tax due by the Holder with respect to such Warrant Shares.

                                      -2-
<PAGE>

                  (b) Exercise Price. For purposes of this Warrant, "EXERCISE
PRICE" means $3.41, subject to adjustment as provided herein.

                  (c) Company's Failure to Timely Deliver Securities. If the
Company shall fail for any reason or for no reason to issue to the Holder on or
before the Share Delivery Date, a certificate for the number of shares of Common
Stock to which the Holder is entitled and register such shares of Common Stock
on the Company's share register or to credit the Holder's balance account with
DTC for such number of shares of Common Stock to which the Holder is entitled
upon the Holder's exercise of this Warrant, then, in addition to all other
remedies available to the Holder, the Company shall pay in cash to the Holder on
each day after such Share Delivery Date that the issuance of such shares of
Common Stock is not timely effected an amount equal to 2.0% of the product of
(A) the sum of the number of shares of Common Stock not issued to the Holder on
a timely basis and to which the Holder is entitled and (B) the Closing Sale
Price of the shares of Common Stock on the trading day immediately preceding the
last possible date which the Company could have issued such shares of Common
Stock to the Holder without violating Section 1(a). In addition to the
foregoing, if on or before the Share Delivery Date the Company shall fail to
issue and deliver a certificate to the Holder and register such shares of Common
Stock on the Company's share register or credit the Holder's balance account
with DTC for the number of shares of Common Stock to which the Holder is
entitled upon such holder's exercise hereunder, and if on or after such Share
Delivery Date the Holder purchases (in an open market transaction or otherwise)
shares of Common Stock to deliver in satisfaction of a sale by the Holder of
shares of Common Stock issuable upon such exercise that the Holder anticipated
receiving from the Company (a "BUY-IN"), then the Company shall, within three
Business Days after the Holder's request and in the Holder's discretion, either
(i) pay cash to the Holder in an amount equal to the Holder's total purchase
price (including brokerage commissions, if any) for the shares of Common Stock
so purchased (the "BUY-IN PRICE"), at which point the Company's obligation to
deliver such certificate (and to issue such shares of Common Stock) shall
terminate, or (ii) promptly honor its obligation to deliver to the Holder a
certificate or certificates representing such shares of Common Stock and pay
cash to the Holder in an amount equal to the excess (if any) of the Buy-In Price
over the product of (A) such number of shares of Common Stock, times (B) the
Closing Bid Price on the date of exercise.

                  (d) Cashless Exercise. Notwithstanding anything contained
herein to the contrary, if a Registration Statement (as defined in the
Registration Rights Agreement) covering the Warrant Shares that are the subject
of the Exercise Notice (the "UNAVAILABLE WARRANT SHARES") is not available for
the resale of such Unavailable Warrant Shares, the Holder may, in its sole
discretion, exercise this Warrant in whole or in part and, in lieu of making the
cash payment otherwise contemplated to be made to the Company upon such exercise
in payment of the Aggregate Exercise Price, elect instead to receive upon such
exercise the "Net Number" of shares of Common Stock determined according to the
following formula (a "CASHLESS EXERCISE"):

                  Net Number = (A x B) - (A x C)
                               -----------------
                                       B

                                      -3-
<PAGE>

                  For purposes of the foregoing formula:

            A= the total number of shares with respect to which this Warrant is
            then being exercised.

            B= the Closing Sale Price of the shares of Common Stock (as reported
            by Bloomberg) on the date immediately preceding the date of the
            Exercise Notice.

            C= the Exercise Price then in effect for the applicable Warrant
            Shares at the time of such exercise.

                  (e) Disputes. In the case of a dispute as to the determination
of the Exercise Price or the arithmetic calculation of the Warrant Shares, the
Company shall promptly issue to the Holder the number of Warrant Shares that are
not disputed and resolve such dispute in accordance with Section 12.

                  (f) Limitations on Exercises.

                        (i) Beneficial Ownership. Other than in connection with
                        a Fundamental Transaction pursuant to Section 4(a), the
                        Company shall not effect the exercise of this Warrant,
                        and the Holder shall not have the right to exercise this
                        Warrant, to the extent that after giving effect to such
                        exercise, such Person (together with such Person's
                        affiliates) would beneficially own in excess of 4.99%
                        (the "MAXIMUM PERCENTAGE") of the shares of Common Stock
                        outstanding immediately after giving effect to such
                        exercise. For purposes of the foregoing sentence, the
                        aggregate number of shares of Common Stock beneficially
                        owned by such Person and its affiliates shall include
                        the number of shares of Common Stock issuable upon
                        exercise of this Warrant with respect to which the
                        determination of such sentence is being made, but shall
                        exclude shares of Common Stock which would be issuable
                        upon (i) exercise of the remaining, unexercised portion
                        of this Warrant beneficially owned by such Person and
                        its affiliates and (ii) exercise or conversion of the
                        unexercised or unconverted portion of any other
                        securities of the Company beneficially owned by such
                        Person and its affiliates (including, without
                        limitation, any convertible notes or convertible
                        preferred stock or warrants) subject to a limitation on
                        conversion or exercise analogous to the limitation
                        contained herein. Except as set forth in the preceding
                        sentence, for purposes of this paragraph, beneficial
                        ownership shall be calculated in accordance with Section
                        13(d) of the Securities Exchange Act of 1934, as
                        amended. For purposes of this Warrant, in determining
                        the number of outstanding shares of Common Stock, the
                        Holder may rely on the number of outstanding shares of
                        Common Stock as reflected in (1) the Company's most
                        recent Form 10-K, Form 10-Q, Current Report on Form 8-K
                        or other

                                      -4-
<PAGE>

                        public filing with the Securities and Exchange
                        Commission, as the case may be, (2) a more recent public
                        announcement by the Company or (3) any other notice by
                        the Company or the Transfer Agent setting forth the
                        number of shares of Common Stock outstanding. For any
                        reason at any time, upon the written or oral request of
                        the Holder, the Company shall within one Business Day
                        confirm orally and in writing to the Holder the number
                        of shares of Common Stock then outstanding. In any case,
                        the number of outstanding shares of Common Stock shall
                        be determined after giving effect to the conversion or
                        exercise of securities of the Company, including the SPA
                        Securities and the SPA Warrants, by the Holder and its
                        affiliates since the date as of which such number of
                        outstanding shares of Common Stock was reported. By
                        written notice to the Company, the Holder may increase
                        or decrease the Maximum Percentage to any other
                        percentage not in excess of 9.99% specified in such
                        notice; provided that (i) any such increase will not be
                        effective until the sixty-first (61st) day after such
                        notice is delivered to the Company, and (ii) any such
                        increase or decrease will apply only to the Holder and
                        not to any other holder of SPA Securities.

                        (ii) Principal Market Regulation. The Company shall not
                        be obligated to issue any shares of Common Stock upon
                        exercise of this Warrant if the issuance of such shares
                        of Common Stock would exceed that number of shares of
                        Common Stock which the Company may issue upon exercise
                        or conversion, as applicable, of the SPA Warrants and
                        SPA Securities without breaching the Company's
                        obligations under the rules or regulations of the
                        Principal Market (the "EXCHANGE CAP"),except that such
                        limitation shall not apply in the event that the Company
                        (A) obtains the approval of its shareholders as required
                        by the applicable rules of the Principal Market for
                        issuances of shares of Common Stock in excess of such
                        amount or (B) obtains a written opinion from outside
                        counsel to the Company that such approval is not
                        required, which opinion shall be reasonably satisfactory
                        to the Required Holders. Until such approval or written
                        opinion is obtained, no Buyer shall be issued in the
                        aggregate, upon exercise or conversion, as applicable,
                        of any SPA Warrants or SPA Securities, shares of Common
                        Stock in an amount greater than the product of the
                        Exchange Cap multiplied by a fraction, the numerator of
                        which is the total number of shares of Common Stock
                        underlying the SPA Warrants issued to such Buyer
                        pursuant to the Securities Purchase Agreement on the
                        Issuance Date and the denominator of which is the
                        aggregate number of shares of Common Stock underlying
                        the SPA Warrants issued to the Buyers pursuant to the
                        Securities Purchase Agreement on the Issuance Date (with
                        respect to each Buyer, the "EXCHANGE CAP ALLOCATION").
                        In the event that

                                      -5-
<PAGE>

                        any Buyer shall sell or otherwise transfer any of such
                        Buyer's SPA Warrants, the transferee shall be allocated
                        a pro rata portion of such Buyer's Exchange Cap
                        Allocation, and the restrictions of the prior sentence
                        shall apply to such transferee with respect to the
                        portion of the Exchange Cap Allocation allocated to such
                        transferee. In the event that any holder of SPA Warrants
                        shall exercise all of such holder's SPA Warrants into a
                        number of shares of Common Stock which, in the
                        aggregate, is less than such holder's Exchange Cap
                        Allocation, then the difference between such holder's
                        Exchange Cap Allocation and the number of shares of
                        Common Stock actually issued to such holder shall be
                        allocated to the respective Exchange Cap Allocations of
                        the remaining holders of SPA Warrants on a pro rata
                        basis in proportion to the shares of Common Stock
                        underlying the SPA Warrants then held by each such
                        holder. In the event that the Company is prohibited from
                        issuing any Warrant Shares for which an Exercise Notice
                        has been received as a result of the operation of this
                        Section 1(f)(ii), the Company shall pay cash in exchange
                        for cancellation of such Warrant Shares, at a price per
                        Warrant Share equal to the difference between the
                        Closing Sale Price and the Exercise Price as of the date
                        of the attempted exercise.

            2. ADJUSTMENT OF EXERCISE PRICE AND NUMBER OF WARRANT SHARES. The
Exercise Price and the number of Warrant Shares shall be adjusted from time to
time as follows:

                  (a) Adjustment upon Issuance of shares of Common Stock. If and
whenever on or after the Subscription Date the Company issues or sells, or in
accordance with this Section 2 is deemed to have issued or sold, any shares of
Common Stock (including the issuance or sale of shares of Common Stock owned or
held by or for the account of the Company, but excluding shares of Common Stock
deemed to have been issued by the Company in connection with any Excluded
Securities (as defined in the SPA Securities) for a consideration per share less
than a price (the "APPLICABLE PRICE") equal to the Exercise Price in effect
immediately prior to such issue or sale or deemed issuance or sale (the
foregoing a "DILUTIVE ISSUANCE"), then immediately after such Dilutive Issuance,
the Exercise Price then in effect shall be reduced to an amount equal to the
product of (A) the Exercise Price in effect immediately prior to such Dilutive
Issuance and (B) the quotient determined by dividing (1) the sum of (I) the
product derived by multiplying the Exercise Price in effect immediately prior to
such Dilutive Issuance and the number of Common Stock Deemed Outstanding
immediately prior to such Dilutive Issuance plus (II) the consideration, if any,
received by the Company upon such Dilutive Issuance, by (2) the product derived
by multiplying (I) the Exercise Price in effect immediately prior to such
Dilutive Issuance by (II) the number of Common Stock Deemed Outstanding
immediately after such Dilutive Issuance. Upon each such adjustment of the
Exercise Price hereunder, the number of Warrant Shares shall be adjusted to the
number of shares of Common Stock determined by multiplying the Exercise Price in
effect immediately prior to such adjustment by the number of Warrant Shares
acquirable upon exercise of this Warrant immediately prior to such adjustment
and dividing the product thereof by the Exercise Price

                                      -6-
<PAGE>

resulting from such adjustment. For purposes of determining the adjusted
Exercise Price under this Section 2(a), the following shall be applicable:

                  (i) Issuance of Options. If the Company in any manner grants
                  any Options and the lowest price per share for which one share
                  of Common Stock is issuable upon the exercise of any such
                  Option or upon conversion, exercise or exchange of any
                  Convertible Securities issuable upon exercise of any such
                  Option is less than the Applicable Price, then such share of
                  Common Stock shall be deemed to be outstanding and to have
                  been issued and sold by the Company at the time of the
                  granting or sale of such Option for such price per share. For
                  purposes of this Section 2(a)(i), the "lowest price per share
                  for which one share of Common Stock is issuable upon exercise
                  of such Options or upon conversion, exercise or exchange of
                  such Convertible Securities" shall be equal to the sum of the
                  lowest amounts of consideration (if any) received or
                  receivable by the Company with respect to any one share of
                  Common Stock upon the granting or sale of the Option, upon
                  exercise of the Option and upon conversion, exercise or
                  exchange of any Convertible Security issuable upon exercise of
                  such Option. No further adjustment of the Exercise Price or
                  number of Warrant Shares shall be made upon the actual
                  issuance of such Common Stock or of such Convertible
                  Securities upon the exercise of such Options or upon the
                  actual issuance of such Common Stock upon conversion, exercise
                  or exchange of such Convertible Securities.

                  (ii) Issuance of Convertible Securities. If the Company in any
                  manner issues or sells any Convertible Securities and the
                  lowest price per share for which one share of Common Stock is
                  issuable upon the conversion, exercise or exchange thereof is
                  less than the Applicable Price, then such share of Common
                  Stock shall be deemed to be outstanding and to have been
                  issued and sold by the Company at the time of the issuance or
                  sale of such Convertible Securities for such price per share.
                  For the purposes of this Section 2(a)(ii), the "lowest price
                  per share for which one share of Common Stock is issuable upon
                  the conversion, exercise or exchange" shall be equal to the
                  sum of the lowest amounts of consideration (if any) received
                  or receivable by the Company with respect to one share of
                  Common Stock upon the issuance or sale of the Convertible
                  Security and upon conversion, exercise or exchange of such
                  Convertible Security. No further adjustment of the Exercise
                  Price or number of Warrant Shares shall be made upon the
                  actual issuance of such Common Stock upon conversion, exercise
                  or exchange of such Convertible Securities, and if any such
                  issue or sale of such Convertible Securities is made upon
                  exercise of any Options for which adjustment of this Warrant
                  has been or is to be made pursuant to other provisions of this
                  Section 2(a), no further adjustment of the Exercise Price or
                  number of Warrant Shares shall be made by reason of such issue
                  or sale.

                                      -7-
<PAGE>

                  (iii) Change in Option Price or Rate of Conversion. If the
                  purchase price provided for in any Options, the additional
                  consideration, if any, payable upon the issue, conversion,
                  exercise or exchange of any Convertible Securities, or the
                  rate at which any Convertible Securities are convertible into
                  or exercisable or exchangeable for shares of Common Stock
                  increases or decreases at any time, the Exercise Price and the
                  number of Warrant Shares in effect at the time of such
                  increase or decrease shall be adjusted to the Exercise Price
                  and the number of Warrant Shares which would have been in
                  effect at such time had such Options or Convertible Securities
                  provided for such increased or decreased purchase price,
                  additional consideration or increased or decreased conversion
                  rate, as the case may be, at the time initially granted,
                  issued or sold. For purposes of this Section 2(a)(iii), if the
                  terms of any Option or Convertible Security that was
                  outstanding as of the date of issuance of this Warrant are
                  increased or decreased in the manner described in the
                  immediately preceding sentence, then such Option or
                  Convertible Security and the shares of Common Stock deemed
                  issuable upon exercise, conversion or exchange thereof shall
                  be deemed to have been issued as of the date of such increase
                  or decrease. No adjustment pursuant to this Section 2(a) shall
                  be made if such adjustment would result in an increase of the
                  Exercise Price then in effect or a decrease in the number of
                  Warrant Shares.

                  (iv) Calculation of Consideration Received. In case any Option
                  is issued in connection with the issue or sale of other
                  securities of the Company, together comprising one integrated
                  transaction in which no specific consideration is allocated to
                  such Options by the parties thereto, the Options will be
                  deemed to have been issued for a consideration of $.01. If any
                  shares of Common Stock, Options or Convertible Securities are
                  issued or sold or deemed to have been issued or sold for cash,
                  the consideration received therefor will be deemed to be the
                  net amount received by the Company therefor. If any shares of
                  Common Stock, Options or Convertible Securities are issued or
                  sold for a consideration other than cash, the amount of such
                  consideration other than cash received by the Company will be
                  the fair value of such consideration, except where such
                  consideration consists of marketable securities, in which case
                  the amount of consideration received by the Company will be
                  the Closing Sale Price of such security on the date of
                  receipt. If any shares of Common Stock, Options or Convertible
                  Securities are issued to the shareholders of the non-surviving
                  entity in connection with any merger in which the Company is
                  the surviving entity, the amount of such consideration will be
                  deemed to be the fair value of the net assets and business of
                  the non-surviving entity, calculated on a going-concern basis,
                  as is attributable to such shares of Common Stock, Options or
                  Convertible Securities, as the case may be. The fair value of
                  any consideration other than cash or securities will be
                  determined jointly by the Company and the Required Holders. If
                  such parties are unable to reach agreement within

                                      -8-
<PAGE>

                  ten (10) days after the occurrence of an event requiring
                  valuation (the "VALUATION EVENT"), the fair value of such
                  consideration will be determined within five (5) Business Days
                  after the tenth day following the Valuation Event by an
                  independent, reputable appraiser jointly selected by the
                  Company and the Required Holders. The determination of such
                  appraiser shall be final and binding upon all parties absent
                  manifest error and the fees and expenses of such appraiser
                  shall be borne one-half by the Company and one-half by the
                  Holders. The consideration received by the Company need not be
                  calculated for shares of Common Stock that are issued or sold
                  or deemed issued or sold to the extent they constitute
                  Excluded Securities.

                  (v) Record Date. If the Company takes a record of the holders
                  of shares of Common Stock for the purpose of entitling them
                  (A) to receive a dividend or other distribution payable in
                  shares of Common Stock, Options or in Convertible Securities
                  or (B) to subscribe for or purchase shares of Common Stock,
                  Options or Convertible Securities, then such record date will
                  be deemed to be the date of the issue or sale of the shares of
                  Common Stock deemed to have been issued or sold upon the
                  declaration of such dividend or the making of such other
                  distribution or the date of the granting of such right of
                  subscription or purchase, as the case may be.

                  (vi) Until such time as the Company receives the Stockholder
                  Approval (as defined in the Securities Purchase Agreement), no
                  adjustment pursuant to Section 2(a) shall cause the Exercise
                  Price to be less than $2.62, as adjusted for any stock
                  dividend, stock split, stock combination, reclassification or
                  similar transaction.

                  (b) Adjustment upon Subdivision or Combination of shares of
Common Stock. If the Company at any time on or after the Subscription Date
subdivides (by any stock split, stock dividend, recapitalization or otherwise)
one or more classes of its outstanding shares of Common Stock into a greater
number of shares, the Exercise Price in effect immediately prior to such
subdivision will be proportionately reduced and the number of Warrant Shares
will be proportionately increased. If the Company at any time on or after the
Subscription Date combines (by combination, reverse stock split or otherwise)
one or more classes of its outstanding shares of Common Stock into a smaller
number of shares, the Exercise Price in effect immediately prior to such
combination will be proportionately increased and the number of Warrant Shares
will be proportionately decreased. Any adjustment under this Section 2(b) shall
become effective at the close of business on the date the subdivision or
combination becomes effective.

                  (c) Other Events. If any event occurs of the type contemplated
by the provisions of this Section 2 but not expressly provided for by such
provisions (including, without limitation, the granting of stock appreciation
rights, phantom stock rights or other rights with equity features), then the
Company's Board of Directors will make an appropriate adjustment in the Exercise
Price and the number of Warrant Shares so as to protect the rights of the
Holder;

                                      -9-
<PAGE>

provided that no such adjustment pursuant to this Section 2(c) will increase the
Exercise Price or decrease the number of Warrant Shares as otherwise determined
pursuant to this Section 2.

            3. RIGHTS UPON DISTRIBUTION OF ASSETS. If the Company shall declare
or make any dividend or other distribution of its assets (or rights to acquire
its assets) to holders of shares of Common Stock, by way of return of capital or
otherwise (including, without limitation, any distribution of cash, stock or
other securities, property or options by way of a dividend, spin off,
reclassification, corporate rearrangement, scheme of arrangement or other
similar transaction) for which adjustment in the Exercise Price of the Warrant
is not otherwise provided hereunder (a "DISTRIBUTION"), at any time after the
issuance of this Warrant, then, in each such case:

                  (a) any Exercise Price in effect immediately prior to the
close of business on the record date fixed for the determination of holders of
shares of Common Stock entitled to receive the Distribution shall be reduced,
effective as of the close of business on such record date, to a price determined
by multiplying such Exercise Price by a fraction of which (i) the numerator
shall be the Closing Bid Price of the shares of Common Stock on the trading day
immediately preceding such record date minus the value of the Distribution (as
determined in good faith by the Company's Board of Directors) applicable to one
share of shares of Common Stock, and (ii) the denominator shall be the Closing
Bid Price of the shares of Common Stock on the trading day immediately preceding
such record date; and

                  (b) the number of Warrant Shares shall be increased to a
number of shares equal to the number of shares of Common Stock obtainable
immediately prior to the close of business on the record date fixed for the
determination of holders of shares of Common Stock entitled to receive the
Distribution multiplied by the reciprocal of the fraction set forth in the
immediately preceding paragraph (a).

            4. FUNDAMENTAL TRANSACTIONS.

                  (a) The Company shall not enter into or be party to a
Fundamental Transaction unless (i) the Successor Entity assumes in writing all
of the obligations of the Company under this Warrant and the other Transaction
Documents in accordance with the provisions of this Section (4)(a) pursuant to
written agreements in form and substance satisfactory to the Required Holders
and approved by the Required Holders prior to such Fundamental Transaction,
including agreements to deliver to each holder of Warrants in exchange for such
Warrants a security of the Successor Entity evidenced by a written instrument
substantially similar in form and substance to this Warrant, including, without
limitation, an adjusted exercise price equal to the value for the shares of
Common Stock reflected by the terms of such Fundamental Transaction, and
exercisable for a corresponding number of shares of capital stock equivalent to
the shares of Common Stock acquirable and receivable upon exercise of this
Warrant (without regard to any limitations on the exercise of this Warrant)
prior to such Fundamental Transaction, and satisfactory to the Required Holders
and (ii) the Successor Entity (including its Parent Entity) is a publicly traded
corporation whose common stock is quoted on or listed for trading on an Eligible
Market. Upon the occurrence of any Fundamental Transaction, the Successor Entity
shall succeed to, and be substituted for (so that from and after the date of
such Fundamental Transaction, the provisions of this Warrant referring to the

                                      -10-
<PAGE>

"Company" shall refer instead to the Successor Entity), and may exercise every
right and power of the Company and shall assume all of the obligations of the
Company under this Warrant with the same effect as if such Successor Entity had
been named as the Company herein. Upon consummation of the Fundamental
Transaction, the Successor Entity shall deliver to the Holder confirmation that
there shall be issued upon exercise of this Warrant at any time after the
consummation of the Fundamental Transaction, in lieu of the shares of the Common
Stock (or other securities, cash, assets or other property) purchasable upon the
exercise of the Warrant prior to such Fundamental Transaction, such shares of
stock, securities, cash, assets or any other property whatsoever (including
warrants or other purchase or subscription rights) which the Holder would have
been entitled to receive upon the happening of such Fundamental Transaction had
this Warrant been exercised immediately prior to such Fundamental Transaction,
as adjusted in accordance with the provisions of this Warrant. In addition to
and not in substitution for any other rights hereunder, prior to the
consummation of any Fundamental Transaction pursuant to which holders of shares
of Common Stock are entitled to receive securities or other assets with respect
to or in exchange for shares of Common Stock (a "CORPORATE EVENT"), the Company
shall make appropriate provision to insure that the Holder will thereafter have
the right to receive upon an exercise of this Warrant at any time after the
consummation of the Fundamental Transaction but prior to the Expiration Date, in
lieu of the shares of the Common Stock (or other securities, cash, assets or
other property) purchasable upon the exercise of the Warrant prior to such
Fundamental Transaction, such shares of stock, securities, cash, assets or any
other property whatsoever (including warrants or other purchase or subscription
rights) which the Holder would have been entitled to receive upon the happening
of such Fundamental Transaction had the Warrant been exercised immediately prior
to such Fundamental Transaction. Provision made pursuant to the preceding
sentence shall be in a form and substance reasonably satisfactory to the
Required Holders. The provisions of this Section shall apply similarly and
equally to successive Fundamental Transactions and Corporate Events. Provision
made pursuant to the preceding sentence shall be in a form and substance
satisfactory to the Required Holders. The provisions of this Section shall apply
similarly and equally to successive Fundamental Transactions and Corporate
Events and shall be applied without regard to any limitations on the exercise of
this Warrant.

                  (b) In the event of a Fundamental Transaction, if the
Successor Entity is unable to deliver to the Holder the warrant referred to in
Section 4(a) and the Holder has not exercised the Warrant in full prior to the
consummation of the Fundamental Transaction, then the Company may enter into a
Fundamental Transaction pursuant to which the Holder shall receive,
simultaneously with the consummation of the Fundamental Transaction, in lieu of
the warrant referred to in Section 4(a) cash in an amount equal to the value of
the remaining unexercised portion of this Warrant on the date of such
consummation, which value shall be determined by use of the Black and Scholes
Option Pricing Model. Provision made pursuant to this Section shall be in a form
and substance reasonably satisfactory to the Required Holders and approved by
the Required Holders prior to such Fundamental Transactions. The provisions of
this Section shall apply similarly and equally to successive Fundamental
Transactions.

            5. NONCIRCUMVENTION. The Company hereby covenants and agrees that
the Company will not, by amendment of its Articles of Incorporation, Bylaws or
through any reorganization, transfer of assets, consolidation, merger, scheme of
arrangement, dissolution, issue or sale of securities, or any other voluntary
action, avoid or seek to avoid the observance or

                                      -11-
<PAGE>

performance of any of the terms of this Warrant, and will at all times in good
faith carry out all the provisions of this Warrant and take all action as may be
required to protect the rights of the Holder. Without limiting the generality of
the foregoing, the Company (i) shall not increase the par value of any shares of
Common Stock receivable upon the exercise of this Warrant above the Exercise
Price then in effect, (ii) shall take all such actions as may be necessary or
appropriate in order that the Company may validly and legally issue fully paid
and nonassessable shares of Common Stock upon the exercise of this Warrant, and
(iii) shall, so long as any of the SPA Warrants are outstanding, take all action
necessary to reserve and keep available out of its authorized and unissued
shares of Common Stock, solely for the purpose of effecting the exercise of the
SPA Warrants, 130% of the number of shares of Common Stock as shall from time to
time be necessary to effect the exercise of the SPA Warrants then outstanding
(without regard to any limitations on exercise).

            6. WARRANT HOLDER NOT DEEMED A STOCKHOLDER. Except as otherwise
specifically provided herein, the Holder, solely in such Person's capacity as a
holder of this Warrant, shall not be entitled to vote or receive dividends or be
deemed the holder of share capital of the Company for any purpose, nor shall
anything contained in this Warrant be construed to confer upon the Holder,
solely in such Person's capacity as the Holder of this Warrant, any of the
rights of a shareholder of the Company or any right to vote, give or withhold
consent to any corporate action (whether any reorganization, issue of stock,
reclassification of stock, consolidation, merger, conveyance or otherwise),
receive notice of meetings, receive dividends or subscription rights, or
otherwise, prior to the issuance to the Holder of the Warrant Shares which such
Person is then entitled to receive upon the due exercise of this Warrant. In
addition, nothing contained in this Warrant shall be construed as imposing any
liabilities on the Holder to purchase any securities (upon exercise of this
Warrant or otherwise) or as a shareholder of the Company, whether such
liabilities are asserted by the Company or by creditors of the Company.
Notwithstanding this Section 6, the Company shall provide the Holder with copies
of the same notices and other information given to the shareholders of the
Company generally, contemporaneously with the giving thereof to the
shareholders.

            7. REISSUANCE OF WARRANTS.

                  (a) Transfer of Warrant. If this Warrant is to be transferred,
the Holder shall surrender this Warrant to the Company, whereupon the Company
will forthwith issue and deliver upon the order of the Holder a new Warrant (in
accordance with Section 7(d)), registered as the Holder may request,
representing the right to purchase the number of Warrant Shares being
transferred by the Holder and, if less then the total number of Warrant Shares
then underlying this Warrant is being transferred, a new Warrant (in accordance
with Section 7(d)) to the Holder representing the right to purchase the number
of Warrant Shares not being transferred.

                  (b) Lost, Stolen or Mutilated Warrant. Upon receipt by the
Company of evidence reasonably satisfactory to the Company of the loss, theft,
destruction or mutilation of this Warrant, and, in the case of loss, theft or
destruction, of any indemnification undertaking by the Holder to the Company in
customary form and, in the case of mutilation, upon surrender and cancellation
of this Warrant, the Company shall execute and deliver to the Holder a new
Warrant

                                      -12-
<PAGE>

(in accordance with Section 7(d)) representing the right to purchase the Warrant
Shares then underlying this Warrant.

                  (c) Exchangeable for Multiple Warrants. This Warrant is
exchangeable, upon the surrender hereof by the Holder at the principal office of
the Company, for a new Warrant or Warrants (in accordance with Section 7(d))
representing in the aggregate the right to purchase the number of Warrant Shares
then underlying this Warrant, and each such new Warrant will represent the right
to purchase such portion of such Warrant Shares as is designated by the Holder
at the time of such surrender; provided, however, that no Warrants for
fractional shares of Common Stock shall be given.

                  (d) Issuance of New Warrants. Whenever the Company is required
to issue a new Warrant pursuant to the terms of this Warrant, such new Warrant
(i) shall be of like tenor with this Warrant, (ii) shall represent, as indicated
on the face of such new Warrant, the right to purchase the Warrant Shares then
underlying this Warrant (or in the case of a new Warrant being issued pursuant
to Section 7(a) or Section 7(c), the Warrant Shares designated by the Holder
which, when added to the number of shares of Common Stock underlying the other
new Warrants issued in connection with such issuance, does not exceed the number
of Warrant Shares then underlying this Warrant), (iii) shall have an issuance
date, as indicated on the face of such new Warrant which is the same as the
Issuance Date, and (iv) shall have the same rights and conditions as this
Warrant.

                                      -13-
<PAGE>

            8. NOTICES. Whenever notice is required to be given under this
Warrant, unless otherwise provided herein, such notice shall be given in
accordance with Section 9(f) of the Securities Purchase Agreement. The Company
shall provide the Holder with prompt written notice of all actions taken
pursuant to this Warrant, including in reasonable detail a description of such
action and the reason therefore. Without limiting the generality of the
foregoing, the Company will give written notice to the Holder (i) immediately
upon any adjustment of the Exercise Price, setting forth in reasonable detail,
and certifying, the calculation of such adjustment and (ii) at least fifteen
days (or such lesser period agreed to in writing by the Required Holders) prior
to the date on which the Company closes its books or takes a record (A) with
respect to any dividend or distribution upon the shares of Common Stock, (B)
with respect to any grants, issuances or sales of any Options, Convertible
Securities or rights to purchase stock, warrants, securities or other property
to all holders of shares of Common Stock or (C) for determining rights to vote
with respect to any Fundamental Transaction, dissolution or liquidation,
provided in each case that such information shall be made known to the public
prior to or in conjunction with such notice being provided to the Holder.

            9. AMENDMENT AND WAIVER. Except as otherwise provided herein, the
provisions of this Warrant may be amended and the Company may take any action
herein prohibited, or omit to perform any act herein required to be performed by
it, only if the Company has obtained the written consent of the Required
Holders; provided that no such action may increase the exercise price of any SPA
Warrant or decrease the number of shares or class of stock obtainable upon
exercise of any SPA Warrant without the written consent of the Holder. No such
amendment shall be effective to the extent that it applies to less than all of
the holders of the SPA Warrants then outstanding.

            10. GOVERNING LAW. This Warrant shall be governed by and construed
and enforced in accordance with, and all questions concerning the construction,
validity, interpretation and performance of this Warrant shall be governed by,
the internal laws of the State of New York, without giving effect to any choice
of law or conflict of law provision or rule (whether of the State of New York or
any other jurisdictions) that would cause the application of the laws of any
jurisdictions other than the State of New York.

            11. CONSTRUCTION; HEADINGS. This Warrant shall be deemed to be
jointly drafted by the Company and all the Buyers and shall not be construed
against any person as the drafter hereof. The headings of this Warrant are for
convenience of reference and shall not form part of, or affect the
interpretation of, this Warrant.

            12. DISPUTE RESOLUTION. In the case of a dispute as to the
determination of the Exercise Price or the arithmetic calculation of the Warrant
Shares, the Company shall submit the disputed determinations or arithmetic
calculations via facsimile within two Business Days of receipt of the Exercise
Notice giving rise to such dispute, as the case may be, to the Holder. If the
Holder and the Company are unable to agree upon such determination or
calculation of the Exercise Price or the Warrant Shares within three Business
Days of such disputed determination or arithmetic calculation being submitted to
the Holder, then the Company shall, within two Business Days submit via
facsimile (a) the disputed determination of the Exercise Price to an
independent, reputable investment bank selected by the Company and approved by
the Holder or (b) the disputed arithmetic calculation of the Warrant Shares to
the Company's independent,

                                      -14-
<PAGE>

outside accountant. The Company shall cause at its expense the investment bank
or the accountant, as the case may be, to perform the determinations or
calculations and notify the Company and the Holder of the results no later than
ten Business Days from the time it receives the disputed determinations or
calculations. Such investment bank's or accountant's determination or
calculation, as the case may be, shall be binding upon all parties absent
demonstrable error.

            13. REMEDIES, OTHER OBLIGATIONS, BREACHES AND INJUNCTIVE RELIEF. The
remedies provided in this Warrant shall be cumulative and in addition to all
other remedies available under this Warrant and the other Transaction Documents,
at law or in equity (including a decree of specific performance and/or other
injunctive relief), and nothing herein shall limit the right of the Holder right
to pursue actual damages for any failure by the Company to comply with the terms
of this Warrant. The Company acknowledges that a breach by it of its obligations
hereunder will cause irreparable harm to the Holder and that the remedy at law
for any such breach may be inadequate. The Company therefore agrees that, in the
event of any such breach or threatened breach, the holder of this Warrant shall
be entitled, in addition to all other available remedies, to an injunction
restraining any breach, without the necessity of showing economic loss and
without any bond or other security being required.

            14. TRANSFER. (a)This Warrant may be offered for sale, sold,
transferred or assigned without the consent of the Company, except as may
otherwise be required by Section 2(f) of the Securities Purchase Agreement. Each
Person to whom this Warrant is sold, assigned or transferred by the Holder shall
provide to the Company true and accurate information as to such Person
comparable to that contained in columns (1), (2) and (7) of the Schedule of
Buyers attached to the Securities Purchase Agreement and as to the jurisdiction
of residence of such Person.

                  (a) The Company shall be entitled to treat the registered
Holder of this Warrant as the absolute owner hereof and shall incur no liability
for the issuance of Common Stock or for other action taken hereunder in good
faith based upon such ownership until such time as a written assignment of this
Warrant is effected by such registered owner, which assignment has been
delivered to the Company and satisfies the requirements of Sections 7(a) and
14(a) hereof.

            15. CERTAIN DEFINITIONS. For purposes of this Warrant, the following
terms shall have the following meanings:

                  (a) "BLOOMBERG" means Bloomberg Financial Markets.

                  (b) "BUSINESS DAY" means any day other than Saturday, Sunday
or other day on which commercial banks in The City of New York are authorized or
required by law to remain closed.

                  (c) "CLOSING BID PRICE" and "CLOSING SALE PRICE" means, for
any security as of any date, the last closing bid price and last closing trade
price, respectively, for such security on the Principal Market, as reported by
Bloomberg, or, if the Principal Market begins to operate on an extended hours
basis and does not designate the closing bid price or the closing

                                      -15-
<PAGE>

trade price, as the case may be, then the last bid price or last trade price,
respectively, of such security prior to 4:00:00 p.m., New York Time, as reported
by Bloomberg, or, if the Principal Market is not the principal securities
exchange or trading market for such security, the last closing bid price or last
trade price, respectively, of such security on the principal securities exchange
or trading market where such security is listed or traded as reported by
Bloomberg, or if the foregoing do not apply, the last closing bid price or last
trade price, respectively, of such security in the over-the-counter market on
the electronic bulletin board for such security as reported by Bloomberg, or, if
no closing bid price or last trade price, respectively, is reported for such
security by Bloomberg, the average of the bid prices, or the ask prices,
respectively, of any market makers for such security as reported in the "pink
sheets" by Pink Sheets LLC (formerly the National Quotation Bureau, Inc.). If
the Closing Bid Price or the Closing Sale Price cannot be calculated for a
security on a particular date on any of the foregoing bases, the Closing Bid
Price or the Closing Sale Price, as the case may be, of such security on such
date shall be the fair market value as mutually determined by the Company and
the Holder. If the Company and the Holder are unable to agree upon the fair
market value of such security, then such dispute shall be resolved pursuant to
Section 12. All such determinations to be appropriately adjusted for any stock
dividend, stock split, stock combination or other similar transaction during the
applicable calculation period.

                  (d) "COMMON STOCK" means (i) the Company's shares of Common
Stock, par value $0.01 per share, and (ii) any share capital into which such
Common Stock shall have been changed or any share capital resulting from a
reclassification of such Common Stock.

                  (e) "COMMON STOCK DEEMED OUTSTANDING" means, at any given
time, the number of shares of Common Stock actually outstanding at such time,
plus the number of shares of Common Stock deemed to be outstanding pursuant to
Sections 2(a)(i) and 2(a)(ii) hereof regardless of whether the Options or
Convertible Securities are actually exercisable at such time, but excluding any
shares of Common Stock owned or held by or for the account of the Company or
issuable upon conversion and exercise, as applicable, of the SPA Securities and
the Warrants.

                  (f) "CONVERTIBLE SECURITIES" means any stock or securities
(other than Options) directly or indirectly convertible into or exercisable or
exchangeable for shares of Common Stock.

                  (g) "ELIGIBLE MARKET" means the Principal Market, The New York
Stock Exchange, Inc., the American Stock Exchange or The Nasdaq SmallCap Market.

                  (h) "EXPIRATION DATE" means the date sixty months after the
Issuance Date or, if such date falls on a day other than a Business Day or on
which trading does not take place on the Principal Market (a "HOLIDAY"), the
next date that is not a Holiday.

                  (i) "FUNDAMENTAL TRANSACTION" means that the Company shall,
directly or indirectly, in one or more related transactions, (i) consolidate or
merge with or into (whether or not the Company is the surviving corporation)
another Person, or (ii) sell, assign, transfer, convey or otherwise dispose of
all or substantially all of the properties or assets of the Company to another
Person, (iii) allow another Person to make a purchase, tender or exchange offer
that is

                                      -16-
<PAGE>

accepted by the holders of more than the 50% of the outstanding shares of Common
Stock (not including any shares of Common Stock held by the Person or Persons
making or party to, or associated or affiliated with the Persons making or party
to, such purchase, tender or exchange offer) or (iv) consummate a stock purchase
agreement or other business combination (including, without limitation, a
reorganization, recapitalization, spin-off or scheme of arrangement) with
another Person whereby such other Person acquires more than the 50% of the
outstanding shares of Common Stock (not including any shares of Common Stock
held by the other Person or other Persons making or party to, or associated or
affiliated with the other Persons making or party to, such stock purchase
agreement or other business combination), or (iv) reorganize, recapitalize or
reclassify its Common Stock.

                  (j) "OPTIONS" means any rights, warrants or options to
subscribe for or purchase shares of Common Stock or Convertible Securities.

                  (k) "PARENT ENTITY" of a Person means an entity that, directly
or indirectly, controls the applicable Person and whose common stock or
equivalent equity security is quoted or listed on an Eligible Market, or, if
there is more than one such Person or Parent Entity, the Person or Parent Entity
with the largest public market capitalization as of the date of consummation of
the Fundamental Transaction.

                  (l) "PERSON" means an individual, a limited liability company,
a partnership, a joint venture, a corporation, a trust, an unincorporated
organization, any other entity and a government or any department or agency
thereof.

                  (m) "PRINCIPAL MARKET" means the Nasdaq National Market.

                  (n) "REGISTRATION RIGHTS AGREEMENT" means that certain
registration rights agreement by and among the Company and the Buyers.

                  (o) "REQUIRED HOLDERS" means the holders of the SPA Warrants
representing at least a majority of shares of Common Stock underlying the SPA
Warrants then outstanding.

                  (p) "SPA SECURITIES" means the Notes issued pursuant to the
Securities Purchase Agreement.

                  (q) "SUCCESSOR ENTITY" means the Person (or, if so elected by
the Required Holders, the Parent Entity) formed by, resulting from or surviving
any Fundamental Transaction or the Person (or, if so elected by the Required
Holders, the Parent Entity) with which such Fundamental Transaction shall have
been entered into.

                            [SIGNATURE PAGE FOLLOWS]

                                      -17-
<PAGE>

      IN WITNESS WHEREOF, the Company has caused this Warrant to Purchase Common
Stock to be duly executed as of the Issuance Date set out above.

                                             VERILINK CORPORATION

                                             By:________________________________
                                                Name:
                                                Title:

<PAGE>

                                                                       EXHIBIT A

                                 EXERCISE NOTICE
            TO BE EXECUTED BY THE REGISTERED HOLDER TO EXERCISE THIS
                        WARRANT TO PURCHASE COMMON STOCK

                              VERILINK CORPORATION

      The undersigned holder hereby exercises the right to purchase
_________________ of the shares of Common Stock ("WARRANT SHARES") of Verilink
Corporation, a Delaware corporation (the "COMPANY"), evidenced by the attached
Warrant to Purchase Common Stock (the "WARRANT"). Capitalized terms used herein
and not otherwise defined shall have the respective meanings set forth in the
Warrant.

      1. Form of Exercise Price. The Holder intends that payment of the Exercise
Price shall be made as:

            ____________ a "Cash Exercise" with respect to _________________
                         Warrant Shares; and/or

            ____________ a "Cashless Exercise" with respect to _______________
                         Warrant Shares.

      2. Payment of Exercise Price. In the event that the holder has elected a
Cash Exercise with respect to some or all of the Warrant Shares to be issued
pursuant hereto, the holder shall pay the Aggregate Exercise Price in the sum of
$___________________ to the Company in accordance with the terms of the Warrant.

      3. Delivery of Warrant Shares. The Company shall deliver to the holder
__________ Warrant Shares in accordance with the terms of the Warrant.

      4. The undersigned confirms that the Warrant Shares have been sold in
compliance with the applicable Registration Statement (as defined in the
Registration Rights Agreement) relative to the registration for resale of such
Warrant Shares.

            Yes ______        No_______

Date: ____________ __, ______

________________________________
  Name of Registered Holder

By: _____________________________
    Name:
    Title:

<PAGE>

                                 ACKNOWLEDGMENT

      The Company hereby acknowledges this Exercise Notice and hereby directs
American Stock Transfer & Trust Company to issue the above indicated number of
shares of Common Stock in accordance with the Transfer Agent Instructions dated
March 21, 2005 from the Company and acknowledged and agreed to by American Stock
Transfer & Trust Company.

                                            VERILINK CORPORATION

                                            By:_________________________________
                                               Name:
                                               Title:

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00081-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00081-of-00352.parquet"}]]